CDER Drug and Biologic Accelerated Approvals  Based on a Surrogate Endpoint,Unnamed: 0,Unnamed: 1,Unnamed: 2,Unnamed: 3,Unnamed: 4,Unnamed: 5,Unnamed: 6,Unnamed: 7,Unnamed: 8,FOR THE TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH NDA 021335
"As of March 31, 2024",,,,,,,,,,
Total Approvals 310,,,,,,,,,,
,,,,,,,,,,
NDA and BLA Accelerated Approvals,,,,,,,,,,
"ApplicationNumber",Proprietary  Name,Established  Name,Applicant,"FDAReceivedDate","AcceleratedApproval Date","Total Time toAccelerated Approval(Months)",Accelerated Approval Indication,Conversion-Withdrawal Status,"Full ApprovalConversion-Withdrawal Date",
"NDA 203469Supplement 37",ICLUSIG,PONATINIB,TAKEDA PHARMACEUTICALS USA INC,9/21/2023,3/19/2024,5.9,"FOR THE TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSEDPHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN COMBINATION WITH CHEMOTHERAPY",Not Yet Converted,,
NDA 217785,REZDIFFRA,RESMETIROM,MADRIGAL PHARMACEUTICALS INC,7/14/2023,3/14/2024,8.0,"IN CONJUNCTION WITH DIET AND EXERCISE, FOR THE TREATMENT OF ADULTSWITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITHMODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3FIBROSIS)",Not Yet Converted,,
"NDA 213217Supplement 11",BRUKINSA,ZANUBRUTINIB,BEIGENE USA INC,5/11/2023,3/7/2024,9.9,"FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORYFOLLICULAR LYMPHOMA (FL), IN COMBINATION WITH OBINUTUZUMAB, AFTERTWO OR MORE LINES OF SYSTEMIC THERAPY",Not Yet Converted,,
"NDA 216059Supplement 1",JAYPIRCA,PIRTOBRUTINIB,LOXO ONCOLOGY INC,6/2/2023,12/1/2023,6.0,"FOR THE TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTICLEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE RECEIVEDAT LEAST TWO PRIOR LINES OF THERAPY, INCLUDING A BTK INHIBITOR AND ABCL-2 INHIBITOR",Not Yet Converted,,
"BLA 125514Supplement 148",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME LLC,8/4/2023,11/7/2023,3.1,"IN COMBINATION WITH TRASTUZUMAB, FLUOROPYRIMIDINE AND PLATINUM-CONTAINING CHEMOTHERAPY, FOR THE FIRST-LINE TREATMENT OF PATIENTSWITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC HER2-POSITIVEGASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA",Not Yet Converted,,
"NDA 214938Supplement 2",VOXZOGO,VOSORITIDE,BIOMARIN PHARMACEUTICAL INC,12/21/2022,10/20/2023,10.0,"INJECTION FOR THE TREATMENT OF ALL PEDIATRIC PATIENTS TO INCREASELINEAR GROWTH IN PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES",Not Yet Converted,,
"NDA 212725Supplement 9",ROZLYTREK,ENTRECTINIB,GENENTECH INC,4/28/2023,10/20/2023,5.7,"FOR TREATMENT OF ADULT AND PEDIATRIC PATIENTS OLDER THAN 1 MONTH OFAGE WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTORKINASE (NTRK) GENE FUSION WITHOUT A KNOWN ACQUIRED RESISTANCEMUTATION AS DETECTED BY AN FDA-APPROVED TEST, ARE METASTATIC ORWHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY, ANDHAVE PROGRESSED FOLLOWING TREATMENT OR HAVE NO SATISFACTORYALTERNATIVE THERAPY, AND FOR A NEW ROUTE AND METHOD OFADMINISTRATION FOR CAPSULES PREPARED AS AN ORAL SUSPENSION",Not Yet Converted,,
NDA 218550,ROZLYTREK,ENTRECTINIB,GENENTECH INC,4/28/2023,10/20/2023,5.7,"FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS OLDER THAN 1MONTH OF AGE WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINERECEPTOR KINASE (NTRK) GENE FUSION WITHOUT A KNOWN ACQUIREDRESISTANCE MUTATION AS DETECTED BY AN FDA-APPROVED TEST, AREMETASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVEREMORBIDITY, AND HAVE PROGRESSED FOLLOWING TREATMENT OR HAVE NOSATISFACTORY ALTERNATIVE THERAPY",Not Yet Converted,,
BLA 761345,ELREXFIO,ELRANATAMAB-BCMM,PFIZER INC,12/19/2022,8/14/2023,7.8,"FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORYMULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST FOUR PRIOR LINES OFTHERAPY, INCLUDING A PROTEASOME INHIBITOR, AN IMMUNOMODULATORYAGENT, AND AN ANTI-CD38 MONOCLONAL ANTIBODY",Not Yet Converted,,
BLA 761342,TALVEY,TALQUETAMAB-TGVS,JANSSEN BIOTECH INC,12/9/2022,8/9/2023,8.0,"FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORYMULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST FOUR PRIOR LINES OFTHERAPY, INCLUDING A PROTEASOME INHIBITOR, AN IMMUNOMODULATORYAGENT AND AN ANTI-CD38 MONOCLONAL ANTIBODY",Not Yet Converted,,
BLA 761309,COLUMVI,GLOFITAMAB-GXBM,"GENENTECH, INC",11/1/2022,6/15/2023,7.4,"FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORYDIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED (DLBCL, NOS)OR LARGE B-CELL LYMPHOMA (LBCL) ARISING FROM FOLLICULAR LYMPHOMA,AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY",Not Yet Converted,,
BLA 761324,EPKINLY,EPCORITAMAB-BYSP,GENMAB US INC,9/21/2022,5/19/2023,7.9,"FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORYDIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED,INCLUDING DLBCL ARISING FROM INDOLENT LYMPHOMA, AND HIGH-GRADE BCELL LYMPHOMA AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY",Not Yet Converted,,
NDA 215887,QALSODY,TOFERSEN,BIOGEN INC,5/25/2022,4/25/2023,11.0,"FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTSWHO HAVE A MUTATION IN THE SUPEROXIDE DISMUTASE 1 (SOD1) GENE",Not Yet Converted,,
"As of March 31, 2024",,,,,,,,,,
Total Approvals 310,,,,,,,,,,
"BLA 125514Supplement 136",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME CORP,10/21/2022,4/3/2023,5.4,"IN COMBINATION WITH ENFORTUMAB VEDOTIN FOR THE TREATMENT OF ADULTPATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMAWHO ARE NOT ELIGIBLE FOR CISPLATIN-CONTAINING CHEMOTHERAPY",Converted,12/15/2023,
"BLA 761137Supplement 18",PADCEV,"ENFORTUMAB VEDOTIANEJFV",ASTELLAS PHARMA US INC,10/21/2022,4/3/2023,5.4,"IN COMBINATION WITH PEMBROLIZUMAB FOR THE TREATMENT OF ADULTPATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER(MUC) WHO ARE NOT ELIGIBLE FOR CISPLATIN-CONTAINING CHEMOTHERAPY",Converted,12/15/2023,
BLA 761334,ZYNYZ,RETIFANLIMAB-DLWR,INCYTE CORP,8/8/2022,3/22/2023,7.4,"FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC OR RECURRENTLOCALLY ADVANCED MERKEL CELL CARCINOMA",Not Yet Converted,,
NDA 216403,FILSPARI,SPARSENTAN,TRAVERE THERAPEUTICS INC,3/17/2022,2/17/2023,11.1,"TO REDUCE PROTEINURIA IN ADULTS WITH PRIMARY IMMUNOGLOBULIN ANEPHROPATHY (IGAN) AT RISK OF RAPID DISEASE PROGRESSION, GENERALLY AURINE PROTEIN TO CREATININE RATIO (UPCR) ≥1.5 G/G",Not Yet Converted,,
NDA 216059,JAYPIRCA,PIRTOBRUTINIB,LOXO ONCOLOGY INC,5/27/2022,1/27/2023,8.0,"FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORYMANTLE CELL LYMPHOMA AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY,INCLUDING A BTK INHIBITOR",Not Yet Converted,,
"NDA 213411Supplement 4",TUKYSA,TUCATINIB,SEAGEN INC,7/19/2022,1/19/2023,6.0,"IN COMBINATION WITH TRASTUZUMAB FOR THE TREATMENT OF ADULT PATIENTSWITH RAS WILD-TYPE, HER2-POSITIVE, UNRESECTABLE OR METASTATICCOLORECTAL CANCER THAT HAS PROGRESSED FOLLOWING TREATMENT WITHFLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY",Not Yet Converted,,
BLA 761269,LEQEMBI,LECANEMAB-IRMB,EISAI INC,5/6/2022,1/6/2023,8.0,FOR THE TREATMENT OF ALZHEIMER’S DISEASE,Converted,7/6/2023,
BLA 761263,LUNSUMIO,MOSUNETUZUMAB-AXGB,GENENTECH INC,4/29/2022,12/22/2022,7.8,"FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORYFOLLICULAR LYMPHOMA AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY",Not Yet Converted,,
NDA 216340,KRAZATI,ADAGRASIB,MIRATI THERAPEUTICS INC,12/14/2021,12/12/2022,11.9,"FOR TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), ASDETERMINED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONEPRIOR SYSTEMIC THERAPY",Not Yet Converted,,
BLA 761310,ELAHERE,"MIRVETUXIMABSORAVTANSINE-GYNX",IMMUNOGEN INC,3/28/2022,11/14/2022,7.6,"FOR THE TREATMENT OF ADULT PATIENTS WITH FOLATE-α (FRα)-POSITIVE,PLATINUM-RESISTANT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARYPERITONEAL CANCER, WHO HAVE RECEIVED ONE TO THREE PRIOR SYSTEMICTREATMENT REGIMENS",Converted,3/22/2024,
BLA 761291,TECVAYLI,TECLISTAMAB-CQYV,JANSSEN BIOTECH INC,12/28/2021,10/25/2022,9.9,"FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORYMULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST FOUR PRIOR LINES OFTHERAPY, INCLUDING A PROTEASOME INHIBITOR, AN IMMUNOMODULATORYAGENT, AND AN ANTI-CD38 MONOCLONAL ANTIBODY",Not Yet Converted,,
NDA 214801,LYTGOBI,FUTIBATINIB,TAIHO ONCOLOGY INC,1/31/2022,9/30/2022,8.0,"FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED,UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC INTRAHEPATICCHOLANGIOCARCINOMA HARBORING FIBROBLAST GROWTH FACTOR RECEPTOR2 (FGFR2) GENE FUSIONS OR OTHER REARRANGEMENTS",Not Yet Converted,,
"NDA 213246Supplement 8",RETEVMO,SELPERCATINIB,LOXO ONCOLOGY INC,5/31/2022,9/21/2022,3.7,"FOR ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORSWITH A RET GENE FUSION THAT HAVE PROGRESSED ON OR FOLLOWING PRIORSYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVETREATMENT OPTIONS",Not Yet Converted,,
"BLA 761139Supplement 21",ENHERTU,"FAM-TRASTUZUMABDERUXTECAN-NXKI",DAIICHI SANKYO INC,2/16/2022,8/11/2022,5.8,"FOR THE TREATMENT OF ADULT PATIENTS WITH UNRESECTABLE ORMETASTATIC NON SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE ANACTIVATING HER2 (ERBB2) MUTATION, AS DETECTED BY AN FDA-APPROVEDTEST, AND WHO HAVE RECEIVED A PRIOR SYSTEMIC THERAPY",Not Yet Converted,,
"NDA 216387Original 2",CALQUENCE,ACALABRUTINIB,ASTRAZENECA UK LTD,10/4/2021,8/3/2022,10.0,"FOR THE TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL)WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY",Not Yet Converted,,
"NDA 202806Supplement 22",TAFINLAR,DABRAFENIB,NOVARTIS PHARMACEUTICALS CORP,9/22/2021,6/22/2022,9.0,"IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF ADULT ANDPEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH UNRESECTABLE ORMETASTATIC SOLID TUMORS WITH BRAF V600E MUTATION WHO HAVEPROGRESSED FOLLOWING PRIOR TREATMENT AND HAVE NO SATISFACTORYALTERNATIVE TREATMENT OPTIONS",Not Yet Converted,,
"As of March 31, 2024",,,,,,,,,,
Total Approvals 310,,,,,,,,,,
"NDA 204114Supplement 24",MEKINIST,TRAMETINIB,NOVARTIS PHARMACEUTICALS CORP,9/22/2021,6/22/2022,9.0,"IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF ADULT ANDPEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH UNRESECTABLE ORMETASTATIC SOLID TUMORS WITH BRAF V600E MUTATION WHO HAVEPROGRESSED FOLLOWING PRIOR TREATMENT AND HAVE NO SATISFACTORYALTERNATIVE TREATMENT OPTIONS",Not Yet Converted,,
NDA 215039,VIJOICE,ALPELISIB,NOVARTIS PHARMACEUTICALS CORP,10/6/2021,4/5/2022,6.0,"FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE ANDOLDER WITH SEVERE MANIFESTATIONS OF PIK3CA-RELATED OVERGROWTHSPECTRUM (PROS) WHO REQUIRE SYSTEMIC THERAPY",Not Yet Converted,,
NDA 208712,VONJO,PACRITINIB,CTI BIOPHARMA CORP,3/30/2021,2/28/2022,11.0,"FOR THE TREATMENT OF ADULTS WITH INTERMEDIATE OR HIGH-RISK PRIMARYOR SECONDARY (POST-POLYCYTHEMIA VERA OR POST-ESSENTIALTHROMBOCYTHEMIA) MYELOFIBROSIS WITH A PLATELET COUNT BELOW 50 ×109/L",Not Yet Converted,,
"NDA 213137Supplement 6",OXBRYTA (tablets),VOXELOTOR,GLOBAL BLOOD THERAPEUTICS INC,6/25/2021,12/17/2021,5.8,"FOR THE TREATMENT OF SICKLE CELL DISEASE IN ADULTS AND PEDIATRICPATIENTS 4 YEARS OF AGE AND OLDER",Not Yet Converted,,
NDA 216157,"OXBRYTA(tablets for oralsuspension)",VOXELOTOR,GLOBAL BLOOD THERAPEUTICS INC,6/25/2021,12/17/2021,5.8,"FOR THE TREATMENT OF SICKLE CELL DISEASE IN ADULTS AND PEDIATRICPATIENTS 4 YEARS OF AGE AND OLDER",Not Yet Converted,,
NDA 215935,TARPEYO,BUDESONIDE,CALLIDITAS THERAPEUTICS AB,3/15/2021,12/15/2021,9.0,"TO REDUCE PROTEINURIA IN ADULTS WITH PRIMARY IMMUNOGLOBULIN ANEPHROPATHY (IGAN) AT RISK OF RAPID DISEASE PROGRESSION, GENERALLY AURINE PROTEIN-TO-CREATININE RATIO (UPCR) ≥ 1.5 G/G",Converted,12/20/2023,
NDA 214938,VOXZOGO,VOSORITIDE,BIOMARIN PHARMACEUTICAL INC,8/20/2020,11/19/2021,15.0,"TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIAWHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES",Not Yet Converted,,
"NDA 215358Original 1",SCEMBLIX,ASCIMINIB,NOVARTIS PHARMACEUTICALS CORP,6/24/2021,10/29/2021,4.2,"FOR THE TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) IN CHRONIC PHASE (CP),PREVIOUSLY TREATED WITH TWO OR MORE TYROSINE KINASE INHIBITORS (TKIS)",Converted,10/12/2022,
BLA 761208,TIVDAK,"TISOTUMAB VEDOTIN-TFTV",SEAGEN INC,2/10/2021,9/20/2021,7.3,"FOR THE TREATMENT OF ADULT PATIENTS WITH RECURRENT OR METASTATICCERVICAL CANCER WITH DISEASE PROGRESSION ON OR AFTER CHEMOTHERAPY",Not Yet Converted,,
NDA 215310,EXKIVITY,MOBOCERTINIB,TAKEDA PHARMACEUTICALS USA INC,2/26/2021,9/15/2021,6.6,"FOR THE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED ORMETASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR EXON 20INSERTION MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, WHOSEDISEASE HAS PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY",Not Yet Converted,,
"NDA 213217Supplement 5",BRUKINSA,ZANUBRUTINIB,BEIGENE USA INC,3/19/2021,9/14/2021,5.9,"FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORYMARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE ANTI-CD20-BASED REGIMEN",Not Yet Converted,,
BLA 761223,JEMPERLI,DOSTARLIMAB-GXLY,GLAXOSMITHKLINE LLC,12/18/2020,8/17/2021,8.0,"FOR THE TREATMENT OF ADULT PATIENTS WITH MISMATCH REPAIR DEFICIENT(DMMR) RECURRENT OR ADVANCED SOLID TUMORS, AS DETERMINED BY ANFDAAPPROVED TEST, THAT HAVE PROGRESSED ON OR FOLLOWING PRIORTREATMENT AND WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENTOPTIONS",Not Yet Converted,,
BLA 761178,ADUHELM,ADUCANUMAB-AVWA,BIOGEN INC,7/7/2020,6/7/2021,11.0,FOR THE TREATMENT OF ALZHEIMER’S DISEASE,Not Yet Converted,,
NDA 214622,TRUSELTIQ,INFIGRATINIB,QED THERAPEUTICS INC,9/29/2020,5/28/2021,7.9,"FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED,UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMAWITH FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) GENE FUSIONS OROTHER REARRANGEMENT AS DETECTED BY AN FDA APPROVED TEST",Not Yet Converted,,
NDA 214665,LUMAKRAS,SOTORASIB,AMGEN INC,12/16/2020,5/28/2021,5.4,"FOR TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), ASDETERMINED BY AN FDA-APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONEPRIOR SYSTEMIC THERAPY",Not Yet Converted,,
BLA 761210,RYBREVANT,AMIVANTAMAB-VMJW,JANSSEN BIOTECH INC,11/24/2020,5/21/2021,5.9,"FOR TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED ORMETASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMALGROWTH FACTOR RECEPTOR (EGFR) EXON 20 INSERTION MUTATIONS, ASDETECTED BY AN FDA-APPROVED TEST, WHOSE DISEASE HAS PROGRESSED ONOR AFTER PLATINUM-BASED CHEMOTHERAPY",Converted,3/1/2024,
"BLA 125514Supplement 97",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME CORP,11/6/2020,5/5/2021,5.9,"IN COMBINATION WITH TRASTUZUMAB AND FLUOROPYRIMIDINE AND PLATINUMCONTAINING CHEMOTHERAPY, FOR THE FIRST-LINE TREATMENT OF PATIENTSWITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC HER2 POSITIVEGASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA",Not Yet Converted,,
BLA 761196,ZYNLONTA,"LONCASTUXIMABTESIRINE-LPYL",ADC THERAPEUTICS SA,9/21/2020,4/23/2021,7.0,"FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORYLARGE B-CELL LYMPHOMA AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY,INCLUDING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) NOT OTHERWISESPECIFIED, DLBCL ARISING FROM LOW GRADE LYMPHOMA, AND HIGH-GRADE B-CELL LYMPHOMA",Not Yet Converted,,
"As of March 31, 2024",,,,,,,,,,
Total Approvals 310,,,,,,,,,,
BLA 761174,JEMPERLI,DOSTARLIMAB-GXLY,GLAXOSMITHKLINE LLC,12/19/2019,4/22/2021,16.1,"FOR THE TREATMENT OF ADULT PATIENTS WITH MISMATCH REPAIR DEFICIENT(DMMR) RECURRENT OR ADVANCED ENDOMETRIAL CANCER, AS DETERMINED BYAN FDA APPROVED TEST, THAT HAS PROGRESSED ON OR FOLLOWING PRIORTREATMENT WITH A PLATINUM CONTAINING REGIMEN",Converted,2/9/2023,
"BLA 761115Supplement 9",TRODELVY,"SACITUZUMABGOVITECAN-HZIY",IMMUNOMEDICS INC,11/24/2020,4/13/2021,4.6,"FOR THE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED ORMETASTATIC UROTHELIAL CANCER (MUC) WHO HAVE PREVIOUSLY RECEIVED APLATINUM-CONTAINING CHEMOTHERAPY AND EITHER PROGRAMMED DEATHRECEPTOR-1 (PD-1) OR PROGRAMMED DEATH LIGAND 1 (PD-L1) INHIBITOR",Not Yet Converted,,
"BLA 125557Supplement 18",BLINCYTO,BLINATUMOMAB,AMGEN INC,10/2/2020,3/11/2021,5.3,"PROVIDES FOR A MODIFICATION TO THE B-CELL PRECURSOR ACUTELYMPHOBLASTIC LEUKEMIA (ALL) IN FIRST OR SECOND COMPLETE REMISSIONWITH MINIMAL RESIDUAL DISEASE INDICATION TO REVISE TO PATIENTS WITHCD19- POSITIVE ALL",Converted,6/20/2023,
NDA 214383,PEPAXTO,"MELPHALANFLUFENAMIDE",ONCOPEPTIDES AB,6/30/2020,2/26/2021,7.9,"IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF ADULTPATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVERECEIVED AT LEAST FOUR PRIOR LINES OF THERAPY AND WHOSE DISEASE ISREFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONEIMMUNOMODULATORY AGENT, AND ONE CD-38 DIRECTED MONOCLONALANTIBODY","Not Converted - ApplicationWithdrawn",2/23/2024,
NDA 213026,AMONDYS 45,CASIMERSEN,SAREPTA THERAPEUTICS INC,6/25/2020,2/25/2021,8.1,"FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTSWHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TOEXON 45 SKIPPING",Not Yet Converted,,
"BLA 761097Supplement 9",LIBTAYO,CEMIPLIMAB-RWLC,REGENERON PHARMACEUTICALS INC,9/3/2020,2/9/2021,5.2,"FOR THE TREATMENT OF PATIENTS WITH METASTATIC BASAL CELL CARCINOMA(BCC) PREVIOUSLY TREATED WITH A HEDGEHOG PATHWAY INHIBITOR",Converted,4/28/2023,
"NDA 213176Original 1",U   K  O   N  I Q,U  M   B  R   A  L  I S  IB,TG THERAPEUTICS INC,6/15/2020,2/5/2021,7.7,"FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORYMARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIORANTI-CD20-BASED REGIMEN","Not Converted - ApplicationWithdrawn",5/31/2022,
"NDA 213176Original 2",UKONIQ,UMBRALISIB,TG THERAPEUTICS INC,6/15/2020,2/5/2021,7.7,"FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORYFOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIORLINES OF SYSTEMIC THERAPY","Not Converted - ApplicationWithdrawn",5/31/2022,
NDA 214096,TEPMETKO,TEPOTINIB,EMD SERONO INC,6/29/2020,2/3/2021,7.2,"FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELLLUNG CANCER (NSCLC) HARBORING MESENCHYMAL-EPITHELIAL TRANSITION(MET) EXON 14 SKIPPING ALTERATIONS",Converted,2/15/2024,
"BLA 761145Supplement 2","DARZALEXFASPRO","DARATUMUMAB ANDHYALURONIDASE-FIHJ",JANSSEN BIOTECH INC,9/9/2020,1/15/2021,4.2,"FOR THE TREATMENT OF PATIENTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS INCOMBINATION WITH BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONEIN NEWLY DIAGNOSED PATIENTS",Not Yet Converted,,
NDA 214701,GAVRETO,PRALSETINIB,BLUEPRINT MEDICINES CORP,6/30/2020,12/1/2020,5.1,"FOR THE TREAMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE ANDOLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROIDCANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY","Not Converted - IndicationWithdrawn",7/20/2023,
NDA 214701,GAVRETO,PRALSETINIB,BLUEPRINT MEDICINES CORP,6/30/2020,12/1/2020,5.1,"FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGEAND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROIDCANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINEREFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)",Not Yet Converted,,
BLA 761171,DANYELZA,NAXITAMAB-GQGK,Y-MABS THERAPEUTICS INC,3/31/2020,11/25/2020,7.9,"IN COMBINATION WITH GRANULOCYTE-MACROPHAGE COLONY-STIMULATINGFACTOR (GM-CSF), FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OFAGE AND OLDER AND ADULT PATIENTS WITH RELAPSED OR REFRACTORY HIGH-RISK NEUROBLASTOMA IN THE BONE OR BONE MARROW WHO HAVEDEMONSTRATED A PARTIAL RESPONSE, MINOR RESPONSE, OR STABLE DISEASETO PRIOR THERAPY",Not Yet Converted,,
"BLA 125514Supplement 88",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME CORP,5/28/2020,11/13/2020,5.6,"IN COMBINATION WITH CHEMOTHERAPY, FOR THE TREATMENT OF PATIENTSWITH  LOCALLY RECURRENT UNRESECTABLE OR METASTATIC TRIPLE NEGATIVEBREAST CANCER WHOSE TUMORS EXPRESS PD-L1 [COMBINED POSITIVE SCORE(CPS) ≥10] AS DETERMINED BY AN FDA APPROVED TEST",Converted,7/26/2021,
NDA 213721,GAVRETO,PRALSETINIB,BLUEPRINT MEDICINES CORP,3/23/2020,9/4/2020,5.4,"FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDAAPPROVED TEST",Converted,8/9/2023,
NDA 212154,VILTEPSO,VILTOLARSEN,NIPPON SHINYAKU CO LTD,12/12/2019,8/12/2020,8.0,"FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTSWHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TOEXON 53 SKIPPING",Not Yet Converted,,
NDA 213464,LAMPIT,NIFURTIMOX,BAYER HEALTHCARE PHARMACEUTICALS,12/6/2019,8/6/2020,8.0,"FOR THE TREATMENT OF CHAGAS DISEASE IN PEDIATRIC PATIENTS BIRTH TOLESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 2.5 KG",Converted,6/2/2023,
BLA 761158,BLENREP,"BELANTAMABMAFODOTIN-BLMF","GLAXOSMITHKLINE INTELLECTUALPROPERTY DEVELOPMENT LTD ENGLAND",12/5/2019,8/5/2020,8.0,"FOR THE TREATMENT OF ADULTS WITH RELAPSED OR  REFRACTORY MULTIPLEMYELOMA WHO HAVE RECEIVED AT LEAST FOUR PRIOR THERAPIES INCLUDINGAN ANTI-CD38 MONOCLONAL ANTIBODY, A PROTEASOME INHIBITOR, AND ANIMMUNOMODULATORY AGENT","Not Converted - ApplicationWithdrawn",2/6/2023,
"As of March 31, 2024",,,,,,,,,,
Total Approvals 310,,,,,,,,,,
BLA 761163,MONJUVI,TAFASITAMAB-CXIX,MORPHOSYS US INC,12/30/2019,7/31/2020,7.0,"IN COMBINATION WITH LENALIDOMIDE FOR THE TREATMENT OF ADULT PATIENTSWITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM LOW GRADELYMPHOMA, AND WHO ARE NOT ELIGIBLE FOR AUTOLOGOUS STEM CELLTRANSPLANT (ASCT)",Not Yet Converted,,
"BLA 125514Supplement 92 4",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,6/12/2020,6/24/2020,0.4,"PROVIDES FOR AN ALTERNATE DOSAGE REGIMEN OF 400 MG EVERY 6 WEEKSFOR ADULT PATIENTS WITH RECURRENT OR METASTATIC CUTANEOUSSQUAMOUS CELL CARCINOMA (CSCC) THAT IS NOT CURABLE BY SURGERY ORRADIATION",Converted,12/16/2022,
"NDA 212306Supplement 1",XPOVIO,SELINEXOR,KARYOPHARM THERAPEUTICS INC,12/23/2019,6/22/2020,6.0,"FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORYDIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED,INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2LINES OF SYSTEMIC THERAPY",Not Yet Converted,,
NDA 213400,TAZVERIK,TAZEMETOSTAT,EPIZYME INC,12/18/2019,6/18/2020,6.0,"FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY(R/R) FOLLICULAR LYMPHOMA (FL) WHOSE TUMORS ARE POSITIVE FOR AN EZH2MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVEDAT LEAST 2 PRIOR SYSTEMIC THERAPIES;  and THE TREATMENT OF ADULTPATIENTS WITH R/R FL WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENTOPTIONS",Not Yet Converted,,
"BLA 125514Supplement 71",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,12/16/2019,6/16/2020,6.0,"FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH UNRESECTABLEOR METASTATIC TUMOR MUTATIONAL BURDEN-HIGH (TMB-H) [≥10MUTATIONS/MEGABASE (MUT/MB)] SOLID TUMORS, AS DETERMINED BY AN FDA-APPROVED TEST, THAT HAVE PROGRESSED FOLLOWING PRIOR TREATMENT ANDWHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS",Not Yet Converted,,
"BLA 125514Supplement 90 4",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,6/2/2020,6/16/2020,0.5,"PROVIDES FOR AN ALTERNATE DOSE/SCHEDULE OF 400 MG EVERY 6 WEEKS FORADULT PATIENTS WITH UNRESECTABLE OR METASTATIC TMB-H [≥10MUTATIONS/MEGABASE (MUT/MB)] SOLID TUMORS, AS DETERMINED BY AN FDA-APPROVED TEST, THAT HAVE PROGRESSED FOLLOWING PRIOR TREATMENT ANDWHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS",Converted,12/16/2022,
NDA 213702,ZEPZELCA,LURBINECTEDIN,JAZZ PHARMACEUTICALS IRELAND LTD,12/16/2019,6/15/2020,6.0,"FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC SMALL CELL LUNGCANCER (SCLC) WITH DISEASE PROGRESSION ON OR AFTER PRIOR PLATINUM-BASED CHEMOTHERAPY",Not Yet Converted,,
"NDA 204384Supplement 13",SIRTURO,BEDAQUILINE,JANSSEN RESEARCH AND DEVELOPMENT,11/27/2019,5/27/2020,6.0,"FOR THE TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSISAS PART OF COMBINATION THERAPY, IN ADULT AND PEDIATRIC PATIENTS (12 TOLESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 30 KG) TO INCLUDEPATIENTS ≥ 5 TO <12 YEARS OF AGE AND WEIGHING AT LEAST 15 KG",Not Yet Converted,,
NDA 212269,FERRIPROX,DEFERIPRONE,CHIESI USA INC,7/19/2019,5/19/2020,10.0,"FOR THE TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUETO THALASSEMIA SYNDROMES WHEN CURRENT CHELATION THERAPY ISINADEQUATE",Converted,4/30/2021,
"NDA 209115Supplement 4",RUBRACA,RUCAPARIB,CLOVIS ONCOLOGY,11/15/2019,5/15/2020,6.0,"FOR THE TREATMENT OF ADULT PATIENTS WITH A DELETERIOUS BRCAMUTATION (GERMLINE AND/OR SOMATIC)-ASSOCIATED METASTATIC CASTRATIONRESISTANT PROSTATE CANCER WHO HAVE BEEN TREATED WITH ANDROGENRECEPTOR-DIRECTED THERAPY AND A TAXANE-BASED CHEMOTHERAPY",Not Yet Converted,,
"NDA 204026Supplement 23",POMALYST,POMALIDOMIDE,CELGENE,11/14/2019,5/14/2020,6.0,"FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSISARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY(HAART)",Not Yet Converted,,
"NDA 204026Supplement 24",POMALYST,POMALIDOMIDE,CELGENE,11/19/2019,5/14/2020,5.8,"FOR THE TREATMENT OF KAPOSI’S SARCOMA IN PATIENTS WHO ARE HIV-NEGATIVE",Not Yet Converted,,
NDA 213246,RETEVMO,SELPERCATINIB,LOXO ONCOLOGY INC,12/4/2019,5/8/2020,5.1,"FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGEAND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROIDCANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINEREFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)",Not Yet Converted,,
NDA 213246,RETEVMO,SELPERCATINIB,LOXO ONCOLOGY INC,12/4/2019,5/8/2020,5.1,"FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)",Converted,9/21/2022,
NDA 213246,RETEVMO,SELPERCATINIB,LOXO ONCOLOGY INC,12/4/2019,5/8/2020,5.1,"FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGEAND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARYTHYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY",Not Yet Converted,,
NDA 213591,TABRECTA,CAPMATINIB,NOVARTIS PHARMACEUTICAL CORP,12/10/2019,5/6/2020,4.8,"FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELLLUNG CANCER (NSCLC) WHOSE TUMORS HAVE A MUTATION THAT LEADS TOMESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING AS DETECTEDBY AN FDA-APPROVED TEST",Converted,8/10/2022,
"BLA 125514Supplement 59 4",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,4/18/2019,4/28/2020,12.4,"PROVIDES FOR AN ALTERNATE DOSE/SCHEDULE OF 400MG EVERY 6 WEEKS FORADULT PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA",Converted,12/16/2022,
"As of March 31, 2024",,,,,,,,,,
Total Approvals 310,,,,,,,,,,
"BLA 125514Supplement 60 4",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,4/23/2019,4/28/2020,12.2,"PROVIDES FOR AN ALTERNATE DOSE/SCHEDULE OF 400MG EVERY 6 WEEKS FORADULT PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: HODGKIN LYMPHOMA",Not Yet Converted,,
"BLA 125514Supplement 61 4",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,4/23/2019,4/28/2020,12.2,"PROVIDES FOR AN ALTERNATE DOSE/SCHEDULE OF 400MG EVERY 6 WEEKS FORADULT PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: PRIMARY MEDIASTINALB-CELL LYMPHOMA",Not Yet Converted,,
"BLA 125514Supplement 62 4",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,4/23/2019,4/28/2020,12.2,"PROVIDES FOR AN ALTERNATE DOSE/SCHEDULE OF 400MG EVERY 6 WEEKS FORADULT PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEENPREVIOUSLY TREATED WITH AN ANTI-ANGIOGENIC TYROSINE KINASE INHIBITOR(TKI)",Converted,12/16/2022,
"BLA 125514Supplement 64 4",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,4/23/2019,4/28/2020,12.2,"PROVIDES FOR AN ALTERNATE DOSE/SCHEDULE OF 400MG EVERY 6 WEEKS FORADULT PATIENTS WITH ADVANCED OR METASTATIC GASTRIC ORGASTROESOPHAGEAL JUNCTION ADENOCARCINOMA",Converted,12/16/2022,
"BLA 125514Supplement 69 4",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,9/23/2019,4/28/2020,7.2,"PROVIDES FOR AN ALTERNATE DOSE/SCHEDULE OF 400MG EVERY 6 WEEKS FORADULT PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)",Converted,12/16/2022,
"BLA 125514Supplement 76 4",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,4/14/2020,4/28/2020,0.5,"PROVIDES FOR AN ALTERNATE DOSE/SCHEDULE OF 400MG EVERY 6 WEEKS FORADULT PATIENTS WITH RENAL CELL CANCER (RCC)",Converted,12/16/2022,
"BLA 125514Supplement 77 4",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,4/14/2020,4/28/2020,0.5,"PROVIDES FOR AN ALTERNATE DOSE/SCHEDULE OF 400MG EVERY 6 WEEKS FORADULT PATIENTS WITH ENDOMETRIAL CANCER",Converted,12/16/2022,
"BLA 125514Supplement 78 4",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,4/14/2020,4/28/2020,0.5,"PROVIDES FOR AN ALTERNATE DOSE/SCHEDULE OF 400MG EVERY 6 WEEKS FORADULT PATIENTS WITH ADVANCED CERVICAL CANCER WITH DISEASEPROGRESSION DURING OR FOLLOWING CHEMOTHERAPY",Converted,12/16/2022,
"BLA 125514Supplement 82 4",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,4/15/2020,4/28/2020,0.4,"PROVIDES FOR AN ALTERNATE DOSE/SCHEDULE OF 400MG EVERY 6 WEEKS FORADULT PATIENTS WITH RECURRENT LOCALLY ADVANCED OR METASTATICESOPHAGEAL CANCER WITH DISEASE PROGRESSION ON OR AFTER 2 OR MOREPRIOR LINES OF SYSTEMIC THERAPY",Converted,12/16/2022,
"BLA 125514Supplement 83 4",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,4/20/2020,4/28/2020,0.3,"PROVIDES FOR AN ALTERNATE DOSE/SCHEDULE OF 400MG EVERY 6 WEEKS FORADULT PATIENTS WITH UNRESECTABLE OR METASTATIC MICROSATELLITEINSTABILITY-HIGH (MSI-H) OR MISMATCH REPAIR DEFICIENT (DMMR) SOLIDTUMORS THAT HAVE PROGRESSED FOLLOWING PRIOR TX AND WHO HAVE NOSATISFACTORY ALTERNATIVE TX OPTIONS",Converted,12/16/2022,
"BLA 125514Supplement 63 4",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,4/23/2019,4/28/2020,12.2,"PROVIDES FOR AN ALTERNATE DOSE/SCHEDULE OF 400MG EVERY 6 WEEKS FORADULT PATIENTS WITH MERKEL CELL CARCINOMA",Converted,12/16/2022,
"BLA 125514Supplement 79 4",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,4/14/2020,4/28/2020,0.5,"PROVIDES FOR AN ALTERNATE DOSE/SCHEDULE OF 400MG EVERY 6 WEEKS FORADULT PATIENTS WITH BCG-UNRESPONSIVE, HIGH RISK, NON-MUSCLE INVASIVEBLADDER CANCER (NMIBC) WITH CARCINOMA IN-SITU (CIS) WITH OR WITHOUTPAPILLARY TUMORS WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TOUNDERGO CYSTECTOMY",Converted,12/16/2022,
"BLA 125514Supplement 80 4",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,4/14/2020,4/28/2020,0.5,"PROVIDES FOR AN ALTERNATE DOSE/SCHEDULE OF 400MG EVERY 6 WEEKS FORADULT PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECKSQUAMOUS CELL CARCINOMA (HNSCC) WITH DISEASE PROGRESSION ON ORAFTER PLATINUM-CONTAINING CHEMOTHERAPY",Converted,12/16/2022,
"BLA 125514Supplement 81 4",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,4/15/2020,4/28/2020,0.4,"PROVIDES FOR AN ALTERNATE DOSE/SCHEDULE OF 400MG EVERY 6 WEEKS FORADULT PATIENTS WITH METASTATIC SCLC WITH DISEASE PROGRESSION ON ORAFTER PLATINUM-BASED CHEMOTHERAPY AND AT LEAST ONE OTHER LINE OFTHERAPY",Converted,12/16/2022,
BLA 761115,TRODELVY,"SACITUZUMABGOVITECAN-HZIY",IMMUNOMEDICS INC,5/18/2018,4/22/2020,23.2,"FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC TRIPLE-NEGATIVEBREAST CANCER (MTNBC) WHO HAVE RECEIVED AT LEAST TWO PRIORTHERAPIES FOR METASTATIC DISEASE",Converted,4/7/2021,
NDA 213736,PEMAZYRE,PEMIGATINIB,INCYTE CORP,9/30/2019,4/17/2020,6.6,"FOR THE TREATMENT OF ADULTS WITH PREVIOUSLY TREATED, UNRESECTABLELOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH AFIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHERREARRANGEMENT AS DETECTED BY AN FDA-APPROVED TEST",Not Yet Converted,,
"NDA 208574Original 2",,ROMIDEPSIN,TEVA PHARMACEUTICALS USA INC,8/18/2015,3/13/2020,54.9,"FOR THE TREATMENT OF PERIPHERAL T-CELL LYMPHOMA (PTCL) IN ADULTPATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY","Not Converted - IndicationWithdrawn",12/8/2021,
"BLA 125377Supplement 108",YERVOY,IPILIMUMAB,BRISTOL MYERS SQUIBB,9/10/2019,3/10/2020,6.0,"IN COMBINATION WITH NIVOLUMAB, FOR THE TREATMENT OF PATIENTS WITHHEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATEDWITH SORAFENIB",Not Yet Converted,,
"BLA 125554Supplement 78",OPDIVO,NIVOLUMAB,BRISTOL MYERS SQUIBB,9/10/2019,3/10/2020,6.0,"IN COMBINATION WITH IPILIMUMAB, FOR THE TREATMENT OF PATIENTS WITHHEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATEDWITH SORAFENIB",Not Yet Converted,,
NDA 211723,TAZVERIK,TAZEMETOSTAT,EPIZYME INC,5/23/2019,1/23/2020,8.1,"FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS AGED 16 YEARS ANDOLDER WITH METASTATIC OR LOCALLY ADVANCED EPITHELIOID SARCOMA NOTELIGIBLE FOR COMPLETE RESECTION",Not Yet Converted,,
BLA 761139,ENHERTU,"FAM-TRASTUZUMABDERUXTECAN-NXKI",DAIICHI SANKYO INC,8/29/2019,12/20/2019,3.7,"FOR THE TREATMENT OF ADULT PATIENTS WITH UNRESECTABLE ORMETASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO ORMORE PRIOR ANTI-HER2-BASED REGIMENS IN THE METASTATIC SETTING",Converted,5/4/2022,
"As of March 31, 2024",,,,,,,,,,
Total Approvals 310,,,,,,,,,,
BLA 761137,PADCEV,"ENFORTUMAB VEDOTIANEJFV",ASTELLAS PHARMA US INC,7/15/2019,12/18/2019,5.1,"FOR THE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED ORMETASTATIC UROTHELIAL CANCER (MUC) WHO HAVE PREVIOUSLY RECEIVED APROGRAMMED DEATH RECEPTOR-1 (PD-1) OR PROGRAMMED DEATH-LIGAND 1(PD-L1) INHIBITOR, AND A PLATINUM-CONTAINING CHEMOTHERAPY IN THENEOADJUVANT/ADJUVANT, LOCALLY ADVANCED OR METASTATIC SETTING",Converted,7/9/2021,
NDA 211970,VYONDYS 53,GOLODIRSEN,SAREPTA THERAPEUTICS INC,12/19/2018,12/12/2019,11.8,"FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTSWHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TOEXON 53 SKIPPING",Not Yet Converted,,
NDA 213137,OXBRYTA,VOXELOTOR,GLOBAL BLOOD THERAPEUTICS INC,6/26/2019,11/25/2019,5.0,"FOR THE TREATMENT OF SICKLE CELL DISEASE IN ADULTS AND PEDIATRICPATIENTS 12 YEARS OF AGE AND OLDER",Not Yet Converted,,
NDA 213217,BRUKINSA,ZANUBRUTINIB,BEIGENE USA INC,6/27/2019,11/14/2019,4.6,"FOR THE TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL)WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY",Not Yet Converted,,
"NDA 206947Supplement 11",LENVIMA,LENVATINIB,EISAI INC,6/17/2019,9/17/2019,3.0,"IN COMBINATION WITH PEMBROLIZUMAB, FOR THE TREATMENT OF PATIENTSWITH ADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITEINSTABILITY-HIGH (MSI-H) OR MISMATCH REPAIR DEFICIENT (DMMR), WHO HAVEDISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOTCANDIDATES FOR CURATIVE SURGERY OR RADIATION",Converted,7/21/2021,
"BLA 125514Supplement 65",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,6/17/2019,9/17/2019,3.0,"IN COMBINATION WITH LENVATINIB, FOR THE TREATMENT OF PATIENTS WITHADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITEINSTABILITY-HIGH (MSI-H) OR MISMATCH REPAIR DEFICIENT (DMMR), WHO HAVEDISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOTCANDIDATES FOR CURATIVE SURGERY OR RADIATION",Converted,7/21/2021,
"NDA 212726Original 1",ROZLYTREK,ENTRECTINIB,GENENTECH INC,12/18/2018,8/15/2019,7.9,"FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGEAND OLDER WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINERECEPTOR KINASE (NTRK) GENE FUSION WITHOUT A KNOWN ACQUIREDRESISTANCE MUTATION, ARE METASTATIC OR WHERE SURGICAL RESECTION ISLIKELY TO RESULT IN SEVERE MORBIDITY, AND HAVE PROGRESSED FOLLOWINGTREATMENT OR HAVE SATISFACTORY ALTERNATIVE THERAPY",Not Yet Converted,,
"NDA 204384Supplement 10",SIRTURO,BEDAQUILINE,"JANSSEN RESEARCH AND DEVELOPMENTLLC",10/11/2018,8/9/2019,9.9,"AS PART OF COMBINATION THERAPY FOR THE TREATMENT OF ADULT ANDPEDIATRIC PATIENTS (12 TO LESS THAN 18 YEARS OF AGE AND WEIGHING ATLEAST 30KG) WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB)",Not Yet Converted,,
NDA 212306,XPOVIO,SELINEXOR,KARYOPHARM THERAPEUTICS INC,8/6/2018,7/3/2019,10.9,"IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF ADULTPATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) WHOHAVE RECEIVED AT LEAST FOUR PRIOR THERAPIES AND WHOSE DISEASE ISREFRACTORY TO AT LEAST TWO PROTEASOME INHIBITORS, AT LEAST TWOIMMUNOMODULATORY AGENTS, AND AN ANTI-CD38 MONOCLONAL ANTIBODY",Converted,12/18/2020,
"BLA 125514Supplement 53",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,12/17/2018,6/17/2019,6.0,"FOR THE TREATMENT OF PATIENTS WITH METASTATIC SMALL CELL LUNGCANCER WITH DISEASE PROGRESSION ON OR AFTER PLATINUM-BASEDCHEMOTHERAPY AND AT LEAST ONE OTHER PRIOR LINE OF THERAPY","Not Converted - IndicationWithdrawn",3/30/2021,
BLA 761121,POLIVY,"POLATUZUMAB VEDOTINPIIQ",GENENTECH,12/19/2018,6/10/2019,5.7,"IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB PRODUCT, FOR THETREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSELARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, AFTER AT LEAST TWOPRIOR THERAPIES",Converted,4/19/2023,
NDA 212018,BALVERSA,ERDAFITINIB,JANSSEN BIOTECH,9/18/2018,4/12/2019,6.8,"FOR THE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED ORMETASTATIC UROTHELIAL CARCINOMA (MUC), THAT HAS: SUSCEPTIBLE FGFR3OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWINGAT LEAST ONE LINE OF PRIOR PLATINUM CONTAINING CHEMOTHERAPY,INCLUDING WITHIN 12 MONTHS OF NEOADJUVANT OR ADJUVANT PLATINUMCONTAINING CHEMOTHERAPY",Converted,1/19/2024,
"BLA 761034Supplement 18",TECENTRIQ,ATEZOLIZUMAB,GENENTECH,9/12/2018,3/8/2019,5.8,"IN COMBINATION WITH PACLITAXEL PROTEIN-BOUND FOR THE TREATMENT OFADULT PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATICTRIPLE-NEGATIVE BREAST CANCER (TNBC) WHOSE TUMORS EXPRESS PD-L1 (PD-L1 STAINED TUMOR-INFILTRATING IMMUNE CELLS [IC] OF ANY INTENSITYCOVERING ≥ 1% OF THE TUMOR AREA), AS DETERMINED BY AN FDA-APPROVEDTEST","Not Converted - IndicationWithdrawn",10/6/2021,
"BLA 125514Supplement 45",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,6/29/2018,12/19/2018,5.7,"FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH RECURRENTLOCALLY ADVANCED OR METASTATIC MERKEL CELL CARCINOMA",Converted,10/12/2023,
NDA 210861,"VITRAKVI(CAPSULES)",LAROTRECTINIB,LOXO ONCOLOGY,3/26/2018,11/26/2018,8.1,"FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORSTHAT HAVE A NEUROTROPHIC RECEPTOR TYROSINE KINASE (NTRK) GENEFUSION WITHOUT A KNOWN ACQUIRED RESISTANCE MUTATION; AREMETASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVEREMORBIDITY; AND HAVE NO SATISFACTORY ALTERNATIVE TREATMENTS OR THATHAVE PROGRESSED FOLLOWING TREATMENT",Not Yet Converted,,
"As of March 31, 2024",,,,,,,,,,
Total Approvals 310,,,,,,,,,,
NDA 211710,"VITRAKVI(ORAL SOLUTION)",LAROTRECTINIB,LOXO ONCOLOGY,3/26/2018,11/26/2018,8.1,"FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORSTHAT HAVE A NEUROTROPHIC RECEPTOR TYROSINE KINASE (NTRK) GENEFUSION WITHOUT A KNOWN ACQUIRED RESISTANCE MUTATION; AREMETASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVEREMORBIDITY; AND HAVE NO SATISFACTORY ALTERNATIVE TREATMENTS OR THATHAVE PROGRESSED FOLLOWING TREATMENT",Not Yet Converted,,
"NDA 208573Supplement 9",VENCLEXTA,VENETOCLAX,ABBVIE,6/25/2018,11/21/2018,4.9,"IN COMBINATION WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINEFOR THE TREATMENT OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)IN ADULTS AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THATPRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY",Converted,10/16/2020,
"BLA 125514Supplement 42",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,5/9/2018,11/9/2018,6.0,"FOR THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA WHOHAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB",Converted,1/25/2024,
NDA 210868,LORBRENA,LORLATINIB,PFIZER,12/5/2017,11/2/2018,10.9,"FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSEDISEASE HAS PROGRESSED ON: • CRIZOTINIB AND AT LEAST ONE OTHER ALKINHIBITOR FOR METASTATIC DISEASE; OR • ALECTINIB AS THE FIRST ALKINHIBITOR THERAPY FOR METASTATIC DISEASE; OR • CERITINIB AS THE FIRSTALK INHIBITOR THERAPY FOR METASTATIC DISEASE",Converted,3/3/2021,
NDA 207356,ARIKAYCE,"AMIKACIN LIPOSOMEINHALATIONSUSPENSION",INSMED,3/28/2018,9/28/2018,6.0,"FOR THE TREATMENT OF MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNGDISEASE AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN INPATIENTS WHO DO NOT ACHIEVE NEGATIVE SPUTUM CULTURES AFTER AMINIMUM OF 6 CONSECUTIVE MONTHS OF A MULTIDRUG BACKGROUND REGIMENTHERAPY. AS ONLY LIMITED CLINICAL SAFETY AND EFFECTIVENESS DATA FORARIKAYCE ARE CURRENTLY AVAILABLE, RESERVE ARIKAYCE FOR USE IN ADULTSWHO HAVE LIMITED OR NO ALTERNATIVE TREATMENT OPTIONS. THIS DRUG ISINDICATED FOR USE IN A LIMITED AND SPECIFIC POPULATION OF PATIENTS. THISINDICATION IS APPROVED UNDER ACCELERATED APPROVAL BASED ONACHIEVING SPUTUM CULTURE CONVERSION (DEFINED AS 3 CONSECUTIVENEGATIVE MONTHLY SPUTUM CULTURES) BY MONTH 6. CLINICAL BENEFIT HASNOT YET BEEN ESTABLISHED",Not Yet Converted,,
NDA 211155,COPIKTRA,DUVELISIB,VERASTEM,2/5/2018,9/24/2018,7.6,"FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORYFOLLICULAR LYMPHOMA (FL) AFTER AT LEAST TWO PRIOR SYSTEMIC THERAPIES","Not Converted - IndicationWithdrawn",12/17/2021,
"BLA 125554Supplement 67",OPDIVO,NIVOLUMAB,BRISTOL MYERS SQUIBB,2/16/2018,8/16/2018,6.0,"FOR THE TREATMENT OF PATIENTS WITH METASTATIC SMALL CELL LUNGCANCER (SCLC) WITH PROGRESSION AFTER PLATINUM-BASED CHEMOTHERAPYAND AT LEAST ONE OTHER LINE OF THERAPY","Not Converted - IndicationWithdrawn",12/29/2020,
NDA 208623,GALAFOLD,MIGALASTAT,AMICUS THERAPEUTICS,12/13/2017,8/10/2018,7.9,"FOR THE TREATMENT OF ADULTS WITH A CONFIRMED DIAGNOSIS OF FABRYDISEASE AND AN AMENABLE GALACTOSIDASE ALPHA GENE (GLA) VARIANTBASED ON IN VITRO ASSAY DATA",Not Yet Converted,,
"BLA 125377Supplement 96",YERVOY,IPILIMUMAB,BRISTOL MYERS SQUIBB,1/10/2018,7/10/2018,6.0,"IN COMBINATION WITH  NIVOLUMAB FOR THE TREATMENT OF ADULTS ANDPEDIATRIC PATIENTS 12 YEARS AND OLDER WITH MICROSATELLITE INSTABILITY-HIGH (MSI H) OR DNA MISMATCH REPAIR DEFICIENT (DMMR), METASTATICCOLORECTAL CANCER THAT HAS PROGRESSED FOLLOWING TREATMENT WITH AFLUOROPYRIMIDINE, OXALIPLATIN, AND IRINOTECAN",Not Yet Converted,,
"BLA 125554Supplement 63",OPDIVO,NIVOLUMAB,BRISTOL MYERS SQUIBB,1/10/2018,7/10/2018,6.0,"IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF ADULTS ANDPEDIATRIC PATIENTS 12 YEARS AND OLDER WITH MICROSATELLITE INSTABILITY-HIGH (MSI H) OR DNA MISMATCH REPAIR DEFICIENT (DMMR), METASTATICCOLORECTAL CANCER THAT HAS PROGRESSED FOLLOWING TREATMENT WITH AFLUOROPYRIMIDINE, OXALIPLATIN, AND IRINOTECAN",Not Yet Converted,,
"BLA 125514Supplement 30",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,10/3/2017,6/13/2018,8.3,"FOR THE TREAMENT OF ADULT AND PEDIATRIC PATIENTS WITH REFRACTORYPRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL), OR WHO HAVERELAPSED AFTER 2 OR MORE PRIOR LINES OF THERAPY",Converted,10/14/2020,
"BLA 125514Supplement 34",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,12/28/2017,6/12/2018,5.5,"FOR THE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATICCERVICAL CANCER WITH DISEASE PROGRESSION ON OR AFTER CHEMOTHERPAYWHOSE TUMORS EXPRESS PD-L1 (CPS > 1) AS DETERMINED BY AN FDA-APPROVED TEST",Converted,10/13/2021,
"NDA 021462Supplement 51",ALIMTA,PEMETREXED DISODIUM,ELI LILLY AND COMPANY,8/3/2017,6/4/2018,10.0,"IN COMBINATION WITH PEMBROLIZUMAB AND CARBOPLATIN, FOR THE FIRST-LINETREATMENT OF METASTATIC, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER",Converted,1/30/2019,
"As of March 31, 2024",,,,,,,,,,
Total Approvals 310,,,,,,,,,,
"BLA 125557Supplement 13",BLINCYTO,BLINATUMOMAB,AMGEN,9/29/2017,3/29/2018,6.0,"FOR THE TREAMENT OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA(ALL)  IN FIRST OR SECOND COMPLETED REMISSION WITH MINIMAL RESIDUALDISEASE (MRD) GREATER OR EQUAL TO 0.1%  IN ADULTS AND CHILDREN",Converted,6/20/2023,
"NDA 210563Original 2",IMBRUVICA,IBRUTINIB,PHARMACYCLICS,8/31/2017,2/16/2018,5.6,"FOR THE TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL)WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY","Not Converted - IndicationWithdrawn",5/18/2023,
"NDA 210563Original 2",IMBRUVICA,IBRUTINIB,PHARMACYCLICS,8/31/2017,2/16/2018,5.6,"FOR THE TREATMENT OF ADULT PATIENTS WITH MARGINAL ZONE LYMPHOMA(MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONEPRIOR ANTI- CD20 BASED THERAPY","Not Converted - IndicationWithdrawn",5/18/2023,
"NDA 203341Supplement 9",BOSULIF,BOSUTINIB,PF PRISM CV,6/26/2017,12/19/2017,5.8,"FOR THE TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONICPHASE (CP) PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUSLEUKEMIA (PH+CML)",Converted,5/14/2021,
NDA 210259,CALQUENCE,ACALABRUTINIB,ASTRAZENECA PHARMACEUTICALS,6/13/2017,10/31/2017,4.6,"FOR THE TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL)WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY",Not Yet Converted,,
"BLA 125554Supplement 41",OPDIVO,NIVOLUMAB,BRISTOL MYERS SQUIBB,3/24/2017,9/22/2017,6.0,"FOR THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA WHOHAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB","Not Converted - IndicationWithdrawn",7/23/2021,
"BLA 125514Supplement 24",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,3/22/2017,9/22/2017,6.0,"FOR THE TREATMENT OF PATIENTS WITH RECURRENT LOCALLY ADVANCED ORMETASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMAWHOSE TUMORS EXPRESS PD-L1 [COMBINED POSITIVE SCORE (CPS) ≥1] ASDETERMINED BY AN FDA-APPROVED TEST, WITH DISEASE PROGRESSION ON ORAFTER TWO OR MORE PRIOR LINES OF THERAPY INCLUDING FLUOROPYRIMIDINE-AND PLATINUM-CONTAINING CHEMOTHERAPY AND IF APPROPRIATE, HER2/NEUTARGETED THERAPY","Not Converted - IndicationWithdrawn",2/4/2022,
NDA 209936,ALIQOPA,COPANLISIB,BAYER HEALTHCARE PHARMACEUTICALS,3/16/2017,9/14/2017,6.0,"FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULARLYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMICTHERAPIES","Not Converted - ApplicationWithdrawn",3/18/2024,
NDA 209570,N/A 1,BENZNIDAZOLE,CHEMO RESEARCH AL C/O EXCELTIS USA,12/29/2016,8/29/2017,8.0,"FOR THE TREATMENT OF CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS),CAUSED BY TRYPANOSOMA CRUZI, IN PEDIATRIC PATIENTS 2 TO 12 YEARS OFAGE",Not Yet Converted,,
"BLA 125554Supplement 34",OPDIVO,NIVOLUMAB,BRISTOL MYERS SQUIBB,2/2/2017,7/31/2017,5.9,"FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDERWITH MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR MISMATCH REPAIRDEFICIENT (DMMR) METASTATIC COLORECTAL CANCER (CRC) THAT HASPROGRESSED FOLLOWING TREATMENT WITH A FLUOROPYRIMIDINE,OXALIPLATIN, AND IRINOTECAN",Not Yet Converted,,
"BLA 125514Supplement 14",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,9/8/2016,5/23/2017,5.4,"FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH UNRESECTABLEOR METASTATIC, MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR MISMATCHREPAIR DEFICIENT SOLID TUMORS THAT HAVE PROGRESSED FOLLOWING PRIORTREATMENT AND WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENTOPTIONS, OR METASTATIC MICROSATELLITE INSTABILITY-HIGH (MSI-H) ORMISMATCH REPAIR DEFICIENT COLORECTAL CANCER THAT HAS PROGRESSEDFOLLOWING TREATMENT WITH A FLUOROPYRIMIDINE, OXALIPLATIN, ANDIRINOTECAN",Converted,3/28/2023,
NDA 207968,JADENU SPRINKLE,DEFERASIROX,NOVARTIS PHARMACEUTICALS,7/21/2016,5/18/2017,9.9,"FOR THE TREATMENT OF CHRONIC IRON OVERLOAD DUE TO BLOODTRANSFUSIONS (TRANSFUSIONAL HEMOSIDEROSIS) IN PATIENTS 2 YEARS OFAGE AND OLDER",Converted,5/11/2018,
NDA 207968,JADENU SPRINKLE,DEFERASIROX,NOVARTIS PHARMACEUTICALS,7/21/2016,5/18/2017,9.9,"FOR THE TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YEARS OFAGE AND OLDER WITH NON-TRANSFUSION-DEPENDENT THALASSEMIA (NTDT)SYNDROMES AND WITH A LIVER IRON CONCENTRATION (LIC) OF AT LEAST 5MILLIGRAMS OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND ASERUM FERRITIN GREATER THAN 300 MCG/L",Converted,7/23/2020,
"BLA 125514Supplement 17",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,12/14/2016,5/18/2017,5.1,"FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATICUROTHELIAL CARCINOMA WHO ARE NOT ELIGIBLE FOR CISPLATIN-CONTAININGCHEMOTHERAPY",Converted,8/31/2021,
"BLA 125514Supplement 16",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,11/10/2016,5/10/2017,6.0,"IN COMBINATION WITH PEMETREXED AND CARBOPLATIN, FOR THE FIRST-LINETREATMENT OF PATIENTS WITH METASTATIC NON-SQUAMOUS, NON-SMALL CELLLUNG CANCER",Converted,8/20/2018,
BLA 761078,BAVENCIO,AVELUMAB,EMD SERONO,12/27/2016,5/9/2017,4.4,"FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATICUROTHELIAL CARCINOMA (UC) WHO: HAVE DISEASE PROGRESSION DURING ORFOLLOWING PLATINUM-CONTAINING CHEMOTHERAPY OR WHO HAVE DISEASEPROGRESSION WITHIN 12 MONTHS OF NEOADJUVANT OR ADJUVANT TREATMENTWITH PLATINUM-CONTAINING CHEMOTHERAPY",Converted,6/30/2020,
"As of March 31, 2024",,,,,,,,,,
Total Approvals 310,,,,,,,,,,
BLA 761069,IMFINZI,DURVALUMAB,ASTRAZENECA PHARMACEUTICALS,10/13/2016,5/1/2017,6.6,"FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATICUROTHELIAL CARCINOMA WHO HAVE DISEASE PROGRESSION DURING ORFOLLOWING PLATINUM-CONTAINING CHEMOTHERAPY OR HAVE DISEASEPROGRESSION WITHIN 12 MONTHS OF NEOADJUVANT OR ADJUVANT TREATMENTWITH PLATINUM-CONTAINING CHEMOTHERAPY","Not Converted - IndicationWithdrawn",2/19/2021,
NDA 208772,ALUNBRIG,BRIGATINIB,ARIAD PHARMACEUTICALS,8/29/2016,4/28/2017,8.0,"FOR TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVEPROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB",Converted,5/22/2020,
"BLA 125554Supplement 31",OPDIVO,NIVOLUMAB,BRISTOL MYERS SQUIBB,12/9/2016,4/25/2017,4.5,"FOR THE TREATMENT OF ADULT PATIENTS WITH CLASSICAL HODGKINLYMPHOMA THAT HAS RELAPSED OR PROGRESSED AFTER: • AUTOLOGOUSHEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) AND BRENTUXIMABVEDOTIN, OR • 3 OR MORE LINES OF SYSTEMIC THERAPY THAT INCLUDESAUTOLOGOUS HSCT",Not Yet Converted,,
"BLA 761034Supplement 1",TECENTRIQ,ATEZOLIZUMAB,GENENTECH,10/31/2016,4/17/2017,5.5,"FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATICUROTHELIAL CARCINOMA WHO ARE NOT ELIGIBLE FOR CISPLATIN-CONTAININGCHEMOTHERAPY, OR HAVE DISEASE PROGRESSION DURING OR FOLLOWING ANYPLATINUM-CONTAINING CHEMOTHERAPY, OR WITHIN 12 MONTHS OFNEOADJUVANT OR ADJUVANT CHEMOTHERAPY","Not Converted - IndicationWithdrawn",12/2/2022,
BLA 761049,BAVENCIO,AVELUMAB,EMD SERONO,9/23/2016,3/23/2017,6.0,"FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS ANDOLDER WITH METASTATIC MERKEL CELL CARCINOMA",Converted,9/6/2023,
"BLA 125514Supplement 15",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,9/15/2016,3/14/2017,5.9,"FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH REFRACTORYCLASSICAL HODGKIN LYMPHOMA, OR WHO HAVE RELAPSED AFTER 3 OR MOREPRIOR LINES OF THERAPY",Converted,10/14/2020,
"BLA 125554Supplement 24",OPDIVO,NIVOLUMAB,BRISTOL MYERS SQUIBB,9/2/2016,2/2/2017,5.0,"FOR THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIALCARCINOMA WHO: HAVE DISEASE PROGRESSION DURING OR FOLLOWINGPLATINUM-CONTAINING CHEMOTHERAPY; HAVE DISEASE PROGRESSION WITHIN12 MONTHS OF NEOADJUVANT OR ADJUVANT TREATMENT WITH PLATINUM-CONTAINING CHEMOTHERAPY",Converted,8/19/2021,
"NDA 205552Supplement 16",IMBRUVICA,IBRUTINIB,PHARMACYCLICS,9/23/2016,1/18/2017,3.8,"FOR THE TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL)WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIORANTI-CD20-BASED THERAPY","Not Converted - IndicationWithdrawn",5/18/2023,
"NDA 209115 5Supplement 4",RUBRACA,RUCAPARIB,CLOVIS ONCOLOGY,6/23/2016,12/19/2016,5.9,"FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION(GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHOHAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES",Converted,4/6/2018,
BLA 761038,LARTRUVO,OLARATUMAB,ELI LILLY AND COMPANY,2/24/2016,10/19/2016,7.8,"IN COMBINATION WITH DOXORUBICIN FOR THE TREATMENT OF ADULT PATIENTSWITH SOFT TISSUE SARCOMA (STS) WITH A HISTOLOGIC SUBTYPE FOR WHICHAN ANTHRACYCLINE-CONTAINING REGIMEN IS APPROPRIATE AND WHICH IS NOTAMENABLE TO CURATIVE TREATMENT WITH RADIOTHERAPY OR SURGERY","Not Converted - ApplicationWithdrawn",2/25/2020,
NDA 206488,EXONDYS 51,ETEPLIRSEN,SAREPTA THERAPEUTICS,6/26/2015,9/19/2016,14.8,"FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTSWHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TOEXON 51 SKIPPING",Not Yet Converted,,
"BLA 125514Supplement 9",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,2/9/2016,8/5/2016,5.9,"FOR THE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATICSQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WITH DISEASEPROGRESSION ON OR AFTER PLATINUM-CONTAINING CHEMOTHERAPY",Converted,6/10/2019,
NDA 207999,OCALIVA,OBETICHOLIC ACID,INTERCEPT PHARMACEUTICALS,6/29/2015,5/27/2016,10.9,"FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATIONWITHURSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATERESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATEUDCA",Not Yet Converted,,
BLA 761034,TECENTRIQ,ATEZOLIZUMAB,GENENTECH,1/12/2016,5/18/2016,4.2,"FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATICUROTHELIAL CARCINOMA WHO HAVE DISEASE PROGRESSION DURING ORFOLLOWING PLATINUM-CONTAINING CHEMOTHERAPY OR HAVE DISEASEPROGRESSION WITHIN 12 MONTHS OF NEOADJUVANT OR ADJUVANT TREATMENTWITH PLATINUM-CONTAINING CHEMOTHERAPY","Not Converted - IndicationWithdrawn",4/13/2021,
"BLA 125554Supplement 19",OPDIVO,NIVOLUMAB,BRISTOL MYERS SQUIBB,3/1/2016,5/17/2016,2.5,"FOR THE TREATMENT OF CLASSICAL HODGKIN LYMPHOMA THAT HAS RELAPSEDOR PROGRESSED AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELLTRANSPLANTATION (HSCT) AND POST-TRANSPLANTATION BRENTUXIMABVEDOTIN",Not Yet Converted,,
NDA 208573,VENCLEXTA,VENETOCLAX,ABBVIE,10/29/2015,4/11/2016,5.4,"FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA(CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVERECEIVED AT LEAST ONE PRIOR THERAPY",Converted,6/8/2018,
NDA 204630,PROVAYBLUE,METHYLENE BLUE,PROVEPHARM SAS,10/9/2015,4/8/2016,6.0,"FOR THE TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH ACQUIREDMETHEMOGLOBINEMIA",Converted,1/8/2024,
"As of March 31, 2024",,,,,,,,,,
Total Approvals 310,,,,,,,,,,
"BLA 125554Supplement 7",OPDIVO,NIVOLUMAB,BRISTOL MYERS SQUIBB,7/23/2015,1/23/2016,6.0,"1) IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF PATEINTS WITHUNRESECTABLE OR METASTATIC MELANOMA TO REMOVE THE RESTRICTION FORTHE TREATMENT OF ONLY PATIENTS WIHT BRAF WILD-TYPE MELANOMA,  2) AS ASINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH BRAF V600 MUTATIONPOSITIVE, UNRESECTABLE OR METASTATIC MELANOMA TO REMOVE THERESTRICTION THAT SUCH PATIENTS SHOULD HAVE DISEASE PROGRESSIONFOLLOWING IPILIMUMAB AND A BRAF INHIBITOR",Converted,3/7/2019,
NDA 208434,ALECENSA,ALECTINIB,HOFFMAN LA ROCHE,7/6/2015,12/11/2015,5.2,"FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVEPROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB",Converted,11/6/2017,
BLA 761036,DARZALEX,DARATUMUMAB,JANSSEN BIOTECH,7/9/2015,11/16/2015,4.3,"FOR TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVEDAT LEAST 3 PRIOR LINES OF THERAPY INCLUDING A PROTEASOME INHIBITORAND AN IMMUNOMODULATORY AGENT OR ARE DOUBLE REFRACTORY TO APROTEASOME INHIBITOR AND AN IMMUNOMODULATORY AGENT",Converted,11/21/2016,
NDA 208065,TAGRISSO,OSIMERTINIB,ASTRAZENECA PHARMACEUTICALS,6/5/2015,11/13/2015,5.3,"FOR THE TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTHFACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE-NON-SMALL-CELL LUNGCANCER (NSCLC), AS DETECTED BY AN FDAAPPROVED TEST, WHO HAVEPROGRESSED ON OR AFTER EGFR TKI THERAPY",Converted,3/30/2017,
BLA 761025,PRAXBIND,IDARUCIZUMAB,"BOEHRINGER INGELHEIMPHARMACEUTICALS",2/19/2015,10/16/2015,7.9,"FOR THE TREATMENT OF  PATIENTS TREATED WITH PRADAXA® WHEN REVERSALOF THE ANTICOAGULANT EFFECTS OF DABIGATRAN IS NEEDED FOR EMERGENCYSURGERY/URGENT PROCEDURES AND IN LIFE-THREATENING ORUNCONTROLLED BLEEDING",Converted,4/12/2018,
"BLA 125514Supplement 5",KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,4/2/2015,10/2/2015,6.0,"FOR THE TREATMENT OF PATIENTS WITH METASTATIC, PD-L1 POSITIVE, NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA-APPROVEDTEST, WITH DISEASE PROGRESSION ON OR AFTER PLATINUM-CONTAININGCHEMOTHERAPY",Converted,10/24/2016,
"BLA 125554Supplement 2",OPDIVO,NIVOLUMAB,BRISTOL MYERS SQUIBB,3/30/2015,9/30/2015,6.0,"IN COMBINATION WITH IPILIMUMAB, FOR THE TREATMENT OF PATIENTS WITHBRAF V600 WILD-TYPE, UNRESECTABLE OR METASTATIC MELANOMA",Converted,3/7/2019,
NDA 208030,FERRIPROX,DEFERIPRONE,APOPHARMA,11/17/2014,9/9/2015,9.7,"FOR THE TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUETO THALASSEMIA SYNDROMES WHEN CURRENT CHELATION THERAPY ISINADEQUATE",Converted,4/30/2021,
NDA 206910,JADENU,DEFERASIROX,NOVARTIS PHARMACEUTICALS,5/30/2014,3/30/2015,10.0,"FOR THE TREATMENT OF CHRONIC IRON OVERLOAD DUE TO BLOODTRANSFUSIONS (TRANSFUSIONAL HEMOSIDEROSIS) IN PATIENTS 2 YEARS OFAGE AND OLDER",Converted,5/11/2018,
NDA 206910,JADENU,DEFERASIROX,NOVARTIS PHARMACEUTICALS,5/30/2014,3/30/2015,10.0,"FOR THE TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YEARS OFAGE AND OLDER WITH NON-TRANSFUSION-DEPENDENT THALASSEMIA (NTDT)SYNDROMES AND WITH A LIVER IRON CONCENTRATION (LIC) OF AT LEAST 5MILLIGRAMS OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND ASERUM FERRITIN GREATER THAN 300 MCG/L",Converted,7/23/2020,
NDA 205353,FARYDAK,PANOBINOSTAT,NOVARTIS PHARMACEUTICALS,3/24/2014,2/23/2015,11.0,"IN COMBINATION WITH BORTEZOMIB (BTZ) AND DEXAMETHASONE(DEX) FOR THETREATMENT OF PATIENTS WITH MULTIPLE MYELOMA (MM) WHO HAVE RECEIVEDAT LEAST 2 PRIOR REGIMENS, INCLUDING BORTEZOMIB AND ANIMMUNOMODULATORY AGENT","Not Converted - ApplicationWithdrawn",3/24/2022,
NDA 207103,IBRANCE,PALBOCICLIB,PFIZER,8/13/2014,2/3/2015,5.7,"IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSALWOMEN WITH ESTROGEN RECEPTOR(ER)-POSITIVE, HUMAN EPIDERMALGROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED BREAST CANCERAS INITIAL ENDOCRINE-BASED THERAPY FOR THEIR METASTATIC DISEASE",Converted,3/31/2017,
BLA 125554,OPDIVO,NIVOLUMAB,BRISTOL MYERS SQUIBB,7/30/2014,12/22/2014,4.8,"FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA ANDDISEASE PROGRESSION FOLLOWING IPILIMUMAB AND, IF BRAF V600 MUTATIONPOSITIVE, A BRAF INHIBITOR",Converted,3/7/2019,
NDA 206162,LYNPARZA,OLAPARIB,ASTRAZENECA PHARMACEUTICALS,2/3/2014,12/19/2014,10.5,"FOR PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINEBRCA MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITHTHREE OR MORE PRIOR LINES OF CHEMOTHERAPY","Not Converted - ApplicationWithdrawn",3/26/2024,
BLA 125557,BLINCYTO,BLINATUMOMAB,AMGEN,9/19/2014,12/3/2014,2.5,"FOR THE TREATMENT OF PHILADELPHIA CHROMOSOME NEGATIVE RELAPSED ORREFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)",Converted,7/11/2017,
BLA 125514,KEYTRUDA,PEMBROLIZUMAB,MERCK SHARP & DOHME,2/27/2014,9/4/2014,6.2,"FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATICMELANOMA AND DISEASE PROGRESSION FOLLOWING IPILIMUMAB AND, IF BRAFV600 MUTATION POSITIVE, A BRAF INHIBITOR",Converted,12/18/2015,
"As of March 31, 2024",,,,,,,,,,
Total Approvals 310,,,,,,,,,,
NDA 205858,ZYDELIG,IDELALISIB,GILEAD SCIENCES,9/11/2013,7/23/2014,10.4,"FOR THE TREATMENT OF RELAPSED FOLLICULAR B-CELL NON-HODGKINLYMPHOMA (FL) IN PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIORSYSTEMIC THERAPIES AND RELAPSED SMALL LYMPHOCYTIC LYMPHOMA (SLL) INPATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES","Not Converted - IndicationWithdrawn",2/18/2022,
NDA 206256,BELEODAQ,BELINOSTAT,SPECTRUM PHARMACEUTICALS,12/9/2013,7/3/2014,6.8,"FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORYPERIPHERAL T-CELL LYMPHOMA",Not Yet Converted,,
NDA 205755,ZYKADIA,CERITINIB,NOVARTIS PHARMACEUTICALS,12/24/2013,4/29/2014,4.1,"FOR THE TREATMENTOF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVEPROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB",Converted,5/26/2017,
NDA 203202,NORTHERA,DROXIDOPA,LUNDBECK NA LTD,9/28/2011,2/18/2014,28.7,"FOR THE TREATMENT OF ORTHOSTATIC DIZZINESS, LIGHTHEADEDNESS, OR THE“FEELING THAT YOU ARE ABOUT TO BLACK OUT” IN ADULT PATIENTS WITHSYMPTOMATIC NEUROGENIC ORTHOSTATICHYPOTENSION CAUSED BY PRIMARY AUTONOMIC FAILURE (PARKINSON'SDISEASE, MULTIPLE SYSTEM ATROPHY,AND PURE AUTONOMIC FAILURE),DOPAMINE BETA-HYDROXYLASE DEFICIENCY, AND NON-DIABETIC AUTONOMICNEUROPATHY",Not Yet Converted,,
"NDA 205552Original 2",IMBRUVICA,IBRUTINIB,PHARMACYCLICS,6/28/2013,2/12/2014,7.5,"FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA(CLL)  WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY",Converted,7/28/2014,
"NDA 202806Supplement 2",TAFINLAR,DABRAFENIB,NOVARTIS PHARMACEUTICALS,7/9/2013,1/9/2014,6.0,"IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITHUNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600KMUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST",Converted,11/20/2015,
"NDA 204114Supplement 1",MEKINIST,TRAMETINIB,NOVARTIS PHARMACEUTICALS,7/8/2013,1/8/2014,6.0,"IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITHUNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600KMUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST",Converted,11/20/2015,
"NDA 205552Original 1",IMBRUVICA,IBRUTINIB,PHARMACYCLICS,6/28/2013,11/13/2013,4.5,FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL),"Not Converted - IndicationWithdrawn",5/18/2023,
"BLA 125409Supplement 51",PERJETA,PERTUZUMAB,GENENTECH,5/1/2013,9/30/2013,5.0,"IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL FOR THE NEOADJUVANTTREATMENT OF PATIENTS WITH HER2-POSITIVE, LOCALLY ADVANCED,INFLAMMATORY, OR EARLY STAGE BREAST CANCER (EITHER GREATER THAN 2CM IN DIAMETER OR NODE POSITIVE) AS PART OF A COMPLETE TREATMENTREGIMEN FOR EARLY BREAST CANCER",Converted,12/20/2017,
"BLA 125151Supplement 184",ELAPRASE,IDURSULFASE,SHIRE  HUMAN GENETIC THERAPIES,9/24/2012,6/24/2013,9.0,"PROVIDES FOR ADDITIONAL SAFETY AND EFFICACY INFORMATION FOR THETREATMENT OF PATIENTS WITH HUNTER SYNDROME 5 YEARS OF AGE ANDYOUNGER",Not Yet Converted,,
NDA 204026,POMALYST,POMALIDOMIDE,CELGENE,4/10/2012,2/8/2013,10.0,"FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVERECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE ANDBORTEZOMIB AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN60 DAYS OF COMPLETION OF THE LAST THERAPY",Converted,4/23/2015,
"NDA 021882Supplement 15",EXJADE,DEFERASIROX,NOVARTIS PHARMACEUTICALS,12/23/2011,1/23/2013,13.1,"FOR THE TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YEARS OFAGE AND OLDER WITH NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT)SYNDROMES AND WITH A LIVER IRON CONCENTRATION (LIC) OF AT LEAST5MILLIGRAMS OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND ASERUM FERRITIN GREATER THAN 300 MCG/L",Converted,7/23/2020,
NDA 204384,SIRTURO,BEDAQUILINE,JANSSEN RESEARCH AND DEVELOPMENT,6/29/2012,12/28/2012,6.0,"FOR THE TREATMENT OF, AS COMBINATION THERAPY, ADULTS (≥ 18 YEARS)WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS(MDR-TB)",Not Yet Converted,,
NDA 203469,ICLUSIG,PONATINIB,ARIAD PHARMACEUTICALS,9/27/2012,12/14/2012,2.6,"FOR THE TREATMENT OF ADULT PATIENTS WITH CHRONIC PHASE, ACCELERATEDPHASE, OR BLAST PHASE CHRONICMYELOID LEUKEMIA (CML) THAT IS RESISTANT OR INTOLERANT TO PRIORTYROSINE KINASE INHIBITOR THERAPY OR PHILADELPHIA CHROMOSOMEPOSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) THAT IS RESISTANT ORINTOLERANT TO PRIOR TYROSINE KINASE INHIBITOR THERAPY",Converted,11/28/2016,
NDA 203585,SYNRIBO,"OMACETAXINEMEPESUCCINATE",TEVA PHARMACEUTICALS INTERNATIONAL,3/30/2012,10/26/2012,6.9,"FOR THE TREATMENT OF ADULT PATIENTS WITH CHRONIC OR ACCELERATEDPHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE AND/ORINTOLERANCE TO TWO OR MORE TYROSINE KINASE INHIBITORS (TKI)",Converted,2/10/2014,
"As of March 31, 2024",,,,,,,,,,
Total Approvals 310,,,,,,,,,,
NDA 203985,AFINITOR DISPERZ,EVEROLIMUS,NOVARTIS PHARMACEUTICALS,2/29/2012,8/29/2012,6.0,"FOR THE TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH TUBEROUSSCLEROSIS COMPLEX (TSC) FOR THE TREATMENT OF SUBEPENDYMAL GIANTCELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUTCANNOT BE CURATIVELY RESECTED",Converted,1/29/2016,
NDA 202497,MARQIBO,"VINCRISTINE SULFATE(LIPOSOMAL)",TALON THERAPEUTICS,7/12/2011,8/9/2012,13.0,"FOR THE TREATMENT OF ADULTS WITH PHILADELPHIA (PH) CHROMOSOMENEGATIVE (-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND RELAPSE ORGREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWOOR GREATHER TREATMENT LINES OF ANTI-LEUKEMIA THERAPIES","Not Converted - ApplicationWithdrawn",5/2/2022,
NDA 202714,KYPROLIS,CARFILZOMIB,ONYX THERAPEUTICS,9/27/2011,7/20/2012,9.8,"FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVERECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND ANIMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASEPROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY",Converted,1/21/2016,
"NDA 022334Supplement 17",AFINITOR,EVEROLIMUS,NOVARTIS PHARMACEUTICALS,12/19/2011,4/26/2012,4.2,"TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUSSCLEROSIS COMPLEX (TSC) NOT REQUIRING IMMEDIATE SURGERY",Converted,2/18/2016,
NDA 021825,FERRIPROX,DEFERIPRONE,APOPHARMA,1/30/2009,10/14/2011,32.4,"FOR THE TREATMENT OF TRANSFUSIONAL IRON OVERLOAD DUE TOTHALASSEMIA SYNDROMES WHEN CURRENT CHELATION THERAPY ISINADEQUATE",Converted,4/30/2021,
NDA 202570,XALKORI,CRIZOTINIB,PF PRISM CV,3/30/2011,8/26/2011,4.9,"FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATICNON-SMALL CELL LUNG CANCER (NSCLC) THAT IS ANAPLASTIC LYMPHOMAKINASE (ALK)-POSITIVE AS DETECTED BY AN FDA APPROVED TEST",Converted,11/20/2013,
BLA 125388,ADCETRIS,BRENTUXIMAB VEDOTIN,SEATTLE GENETICS,2/28/2011,8/19/2011,5.7,"FOR THE TREATMENT OF PATIENTS WITH HODGKIN LYMPHOMA AFTER FAILUREOF AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) OR AFTER FAILURE OF ATLEAST TWO PRIOR MULTI-AGENT CHEMOTHERAPY REGIMENS IN PATIENTS WHOARE NOT ASCT CANDIDATES",Converted,8/17/2015,
"BLA 125388Supplement 6",ADCETRIS,BRENTUXIMAB VEDOTIN,SEATTLE GENETICS,2/28/2011,8/19/2011,5.7,"FOR THE TREATMENT OF PATIENTS WITH SYSTEMIC ANAPLASTIC LARGE CELLLYMPHOMA (sALCL) AFTER FAILURE OF AT LEAST ONE PRIOR MULIT-AGENTCHEMOTHERPAY REGIMEN",Converted,3/20/2018,
"NDA 022393Supplement 4",ISTODAX,ROMIDEPSIN,CELGENE,12/17/2010,6/16/2011,6.0,"THE TREATMENT OF PERIPHERAL T-CELL LYMPHOMA (PTCL) IN PATIENTS WHOHAVE RECEIVED AT LEAST ONE PRIOR THERAPY","Not Converted - IndicationWithdrawn",7/30/2021,
NDA 021945,MAKENA,"HYDROXYPROGESTERONE CAPROATE",AMAG PHARMA USA,4/20/2006,2/3/2011,57.5,"TO REDUCE THE RISK OF PRETERM BIRTH IN WOMEN WITH A SINGLETONPREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERMBIRTH","Not Converted - ApplicationWithdrawn",4/6/2023,
"NDA 022334Supplement 6",AFINITOR,EVEROLIMUS,NOVARTIS PHARMACEUTICALS,4/30/2010,10/29/2010,6.0,"FOR THE TREATMENT OF SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA)ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTICINTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION",Converted,1/29/2016,
"NDA 021986Supplement 8",SPRYCEL,DASATINIB,BRISTOL MYERS SQUIBB,4/28/2010,10/28/2010,6.0,"FOR THE TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PHILADELPHIACHROMOSOME-POSITIVE (PH+) CML IN CHRONIC PHASE",Converted,8/12/2015,
"NDA 022068Supplement 5",TASIGNA,NILOTINIB,NOVARTIS PHARMACEUTICALS,12/21/2009,6/17/2010,5.9,"FOR THE TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITHPHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA INCHRONIC PHASE",Converted,1/27/2015,
"NDA 022059Supplement 7",TYKERB,LAPATINIB,NOVARTIS PHARMACEUTICALS,3/31/2009,1/29/2010,10.0,"TYKERB IN COMBINATION WITH LETROZOLE IS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATICBREAST CANCER THAT OVEREXPRESS THE HER2 RECEPTOR FOR WHOMHORMONAL THERAPY IS INDICATED",Converted,12/6/2018,
BLA 125326,ARZERRA,OFATUMUMAB,NOVARTIS PHARMACEUTICALS,1/30/2009,10/26/2009,8.8,"FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA(CLL) REFRACTORY TO FLUDARABINE AND ALEMTUZUMAB",Converted,4/17/2014,
NDA 022468,FOLOTYN,PRALATREXATE,ALLOS THERAPEUTICS,3/24/2009,9/24/2009,6.0,"FOR THE TREATMENT OF RELAPSED OR REFRACTORY PERIPERAL T-CELLLYMPHOMA",Not Yet Converted,,
"BLA 125085Supplement 169",AVASTIN,BEVACIZUMAB,GENENTECH,11/3/2008,5/5/2009,6.0,"FOR THE TREATMENT OF GLIOBLASTOMA WITH PROGRESSIVE DISEASEFOLLOWING PRIOR THERAPY",Converted,12/5/2017,
"NDA 021588Supplement 25",GLEEVEC,IMATINIB MESYLATE,NOVARTIS PHARMACEUTICALS,6/24/2008,12/19/2008,5.9,"FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETEGROSS RESECTION OF KIT (CD117) POSITIVE GASTROINTESTINAL STROMALTUMORS (GIST)",Converted,1/31/2012,
"As of March 31, 2024",,,,,,,,,,
Total Approvals 310,,,,,,,,,,
NDA 022273,OFORTA,"FLUDARABINEPHOSPHATE",SANOFI AVENTIS,11/19/2007,12/18/2008,13.0,"FOR THE TREATMENT OF ADULTS PTS WITH B CELL CHRONIC LYMPHOCYTICLEUEMIA (CLL) WHOSE DISEASE HAS NOT RESPONDED TO OR WHO HAVE NOTRESPONDED TO OR HAS PROGRESSED DURING OR AFTER TREATMENT WITH ATLEAST ONE STANDARD ALKYLATING-AGENT CONTAINING REGIMEN","Not Converted - ApplicationWithdrawn",12/31/2011,
NDA 022291,PROMACTA,ELTROMBOPAG,NOVARTIS PHARMACEUTICALS,12/19/2007,11/20/2008,11.1,"FOR THE TREATMENT THROMBOCYTOPNEIA IN PATIENTS WITH CHRONIC IMMUNE(IDIOPATHIC) THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENTRESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY",Converted,2/25/2011,
"NDA 021462Supplement 15",ALIMTA,PEMETREXED DISODIUM,ELI LILLY AND COMPANY,8/28/2007,9/26/2008,13.0,"FOR THE TREATMENT OF • NONSQUAMOUS NON-SMALL CELL LUNG CANCER:INITIAL TREATMENT INCOMBINATION WITH CISPLATIN. (1.1)• NONSQUAMOUS NON-SMALL CELL LUNG CANCER AS A SINGLE-AGENT AFTERPRIORCHEMOTHERAPY (1.2)",Converted,7/2/2009,
"NDA 020634Supplement 47",LEVAQUIN,LEVOFLOXACIN,JANSSEN PHARMACEUTICALS,7/5/2007,5/5/2008,10.0,"TO REDUCE THE INCIDENCE OR PROGRESSION OF DISEASE FOLLOWINGEXPOSURE TO AEROSOLIZED BACILLUS ANTHRACIS IN PEDIATRIC PATIENTS (>6MONTH OF AGE AND OLDER)","Not Converted - ApplicationWithdrawn",1/22/2021,
"NDA 020635Supplement 51",LEVAQUIN,LEVOFLOXACIN,JANSSEN PHARMACEUTICALS,7/5/2007,5/5/2008,10.0,"TO REDUCE THE INCIDENCE OR PROGRESSION OF DISEASE FOLLOWINGEXPOSURE TO AEROSOLIZED BACILLUS ANTHRACIS IN PEDIATRIC PATIENTS (>6MONTH OF AGE AND OLDER)","Not Converted - ApplicationWithdrawn",7/21/2017,
"NDA 021721Supplement 15","LEVAQUIN(oral solution)",LEVOFLOXACIN,JANSSEN PHARMACEUTICALS,7/5/2007,5/5/2008,10.0,"TO REDUCE THE INCIDENCE OR PROGRESSION OF DISEASE FOLLOWINGEXPOSURE TO AEROSOLIZED BACILLUS ANTHRACIS IN PEDIATRIC PATIENTS (>6MONTH OF AGE AND OLDER)","Not Converted - ApplicationWithdrawn",7/21/2017,
"BLA 125085Supplement 91",AVASTIN,BEVACIZUMAB,GENENTECH,5/24/2006,2/22/2008,21.0,"NEW INDICATION FOR USE IN COMBINATION WITH PACLITAXEL FOR THETREATMENT OF PATIENTS WHO HAVE NOT RECEIVED CHEMOTHERAPY FORMETASTATIC HER2 NEGATIVE BREAST CANCER","Not Converted - IndicationWithdrawn",11/18/2011,
NDA 022187,INTELENCE,ETRAVIRINE,JANSSEN PRODUCTS LP,7/18/2007,1/18/2008,6.0,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENTOF HIV-1 IINFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS WHO HAVEEVIDENCE OF VIRAL REPLICATIONS AND HIV-1 STRAINS RESISTANT TO NON-NUCLELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) AND OTHERANTIRETROVIRAL AGENT",Converted,11/24/2009,
NDA 022068,TASIGNA,NILOTINIB,NOVARTIS PHARMACEUTICALS,9/29/2006,10/29/2007,13.0,"FOR THE TREATMENT OF CHRONIC PHASE (CP) AND ACCELERATED PHASE (AC)PHILADELPHIA CHROMOSONE POSITIVE CHRONIC MYELOGENOUSLEUKEMIA(CML)IN ADULT PATIENTS RESISTANT TO OR INTOLERANT TO PRIORTHERAPY THAT INCLUDED GLEEVEC (IMATINIB)",Converted,1/14/2011,
NDA 022145,ISENTRESS,RALTEGRAVIR,MERCK SHARP & DOHME,4/13/2007,10/12/2007,6.0,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, FOR THE TREATMENTOF HIV 1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS WHO HAVEEVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO MULTIPLEANTIRETORVIRAL AGENTS",Converted,1/29/2009,
NDA 022128,SELZENTRY,MARAVIROC,VIIV HEALTHCARE,12/20/2006,8/6/2007,7.5,FOR THE TREATMENT OF PATIENTS WITH CCR5-TROPIC HIV-1,Converted,11/25/2008,
"NDA 021588Supplement 16",GLEEVEC,IMATINIB MESYLATE,NOVARTIS PHARMACEUTICALS,3/28/2006,9/27/2006,6.0,"FOR THE TREATMENT OF NEWLY DIAGNOSED PHILADELPHIA POSITIVE CML INPEDIATRIC PATIENTS",Converted,4/1/2011,
BLA 125147,VECTIBIX,PANITUMUMAB,AMGEN,3/29/2006,9/27/2006,6.0,"FOR THE TREATMENT OF EGFR-EXPRESSING, METASTATIC COLORECTALCARCINOMA WITH DISEASE PROGRESSION ON OR FOLLOWINGFLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-CONTAININGCHEMOTHERAPY REGIMENS",Converted,5/23/2014,
NDA 021986,SPRYCEL,DASATINIB,BRISTOL MYERS SQUIBB,12/28/2005,6/28/2006,6.0,"FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH RESISTANCE ORINTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB",Converted,5/21/2009,
NDA 021976,PREZISTA,DARUNAVIR,JANSSEN PRODUCTS LP,12/23/2005,6/23/2006,6.0,"FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION INANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS, SUCH AS THOSEWITH HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR",Converted,10/21/2008,
"NDA 021430Original 1",THALOMID,THALIDOMIDE,CELGENE,12/23/2003,5/25/2006,29.1,"FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLEMYELOMA",Converted,6/19/2014,
"NDA 021968Original 1",SUTENT,SUNITINIB MALEATE,CP PHARMACEUTICALS INTERNATIONAL,8/11/2005,1/26/2006,5.5,FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA,Converted,2/2/2007,
"NDA 020726Supplement 12",FEMARA,LETROZOLE,NOVARTIS PHARMACEUTICALS,6/28/2005,12/28/2005,6.0,"FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONERECEPTOR POSITIVE EARLY BREAST CANCER",Converted,4/30/2010,
NDA 021882,EXJADE,DEFERASIROX,NOVARTIS PHARMACEUTICALS,5/2/2005,11/2/2005,6.0,"FOR THE TREATMENT OF CHRONIC IRON OVERLOAD DUE TO BLOODTRANSFUSIONS IN PATIENTS 2 YEARS OF AGE AND OLDER",Converted,5/11/2018,
"As of March 31, 2024",,,,,,,,,,
Total Approvals 310,,,,,,,,,,
NDA 021877,ARRANON,NELARABINE,GLAXOSMITHKLINE,4/29/2005,10/28/2005,6.0,"FOR THE TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTICLEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOTRESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH  AT LEASTTWO CHEMOTHERAPY REGIMENS",Converted,7/31/2019,
NDA 021814,APTIVUS,TIPRANAVIR,"BOEHRINGER INGELHEIMPHARMACEUTICALS",12/22/2004,6/22/2005,6.0,"CO-ADMINISTERED WITH 200 MG OF RITONAVIR FOR COMBINATIONANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED ADULT PATIENTS WITHEVIDENCE OF VIRAL REPLICATION, WHO ARE HIGHLY TREATMENT-EXPERIENCEDOR HAVE HIV-1 STRAINS RESISTANT TO MULTIPLE PROTEASE INHIBITORS",Converted,10/4/2007,
NDA 021673,CLOLAR,CLOFARABINE,GENZYME,3/30/2004,12/28/2004,9.0,"FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITHRELAPSED OR REFRACTORY ACUTE LYMPHOCYTIC LEUKEMIA AFTER AT LEASTTWO PRIOR REGIMENS",Converted,7/18/2022,
"BLA 125011Supplement 24",BEXXAR,"TOSITUMOMAB ANDIODINE I 131TOSITUMOMAB",GLAXOSMITHKLINE,7/3/2004,12/22/2004,5.7,"EXPAND THE INDICATION TO INCLUDE PATIENTS WITH RELAPSED ORREFRACTORY, LOW GRADE, FOLLICULAR OR TRANSFORMED CD20 POSITIVE NON-HODGKIN'S LYMPHOMA WHO HAVE NOT RECEIVED RITUXIMAB","Not Converted - IndicationWithdrawn",10/23/2013,
"NDA 020634Supplement 35",LEVAQUIN,LEVOFLOXACIN,JANSSEN PHARMACEUTICALS,5/26/2004,11/24/2004,6.0,FOR THE TREATMENT OF INHALATIONAL ANTHRAX (POST-EXPOSURE),"Not Converted - ApplicationWithdrawn",1/22/2021,
"NDA 020635Supplement 35",LEVAQUIN,LEVOFLOXACIN,JANSSEN PHARMACEUTICALS,5/26/2004,11/24/2004,6.0,FOR THE TREATMENT OF INHALATIONAL ANTHRAX (POST-EXPOSURE),"Not Converted - ApplicationWithdrawn",7/21/2017,
"NDA 021721Supplement 3","LEVAQUIN(oral solution)",LEVOFLOXACIN,JANSSEN PHARMACEUTICALS,11/12/2004,11/24/2004,0.4,FOR THE TREATMENT OF INHALATIONAL ANTHRAX (POST-EXPOSURE),"Not Converted - ApplicationWithdrawn",7/21/2017,
"NDA 021272Supplement 2",REMODULIN,TREPROSTINIL SODIUM,UNITED THERAPEUTICS,1/30/2004,11/24/2004,9.8,"PROVIDES FOR ADDING THE INFUSION OF REMODULIN (TREPROSTINIL SODIUM)1, 2.5, 5 & 10 MG/ML INJECTION VIA AN INDWELLING CENTRAL VENOUS CATHETERTO THE LABELING FOR THE TREATMENT OF PULMONARY ARTERIALHYPERTENSION (PAH)",Converted,3/20/2006,
BLA 125104,TYSABRI,NATALIZUMAB,BIOGEN,5/24/2004,11/23/2004,6.0,"FOR THE TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLESCLEROSIS (MS) TO REDUCE THE FREQUENCY OF CLINICAL EXACERBATIONS",Converted,6/5/2006,
"NDA 020726Supplement 11",FEMARA,LETROZOLE,NOVARTIS PHARMACEUTICALS,4/29/2004,10/29/2004,6.0,"FOR THE EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER INPOSTMENOPAUSAL WOMEN WHO HAVE RECEIVED FIVE YEARS OF ADJUVANTTAMOXIFEN THERAPY",Converted,4/30/2010,
NDA 021322,LUVERIS,LUTROPIN ALPHA,EMD SERONO,5/1/2001,10/8/2004,41.3,"CONCOMITANTLY ADMINIISTERED WITH GONAL-F (FOLLITROPIN ALFA FORINJECTION) FOR STIMULATION OF FOLLICULAR DEVELOPMENT IN INFERTILEHYPOGONADOTROPIC HYPOGONADAL WOMEN WITH PROFOUND LHDEFICIENCY(LH < 1.2 IU/L)","Not Converted - ApplicationWithdrawn",4/12/2016,
"NDA 021677Original 1",ALIMTA,PEMETREXED DISODIUM,ELI LILLY AND COMPANY,11/4/2003,8/19/2004,9.5,"AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH LOCALLYADVANCED OR METASTATAIC NON-SMALL CELL LUNG CANCER AFTER PRIORCHEMOTHERPY",Converted,7/2/2009,
NDA 021752,TRUVADA,"TENOFOVIR DISOPROXILFUMARATE;EMTRICITABINE",GILEAD SCIENCES,3/12/2004,8/2/2004,4.7,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENTOF HIV INFECTION IN ADULTS",Converted,3/8/2006,
BLA 125084,ERBITUX,CETUXIMAB,ELI LILLY AND COMPANY,8/14/2003,2/12/2004,6.0,"IN COMBINATION WITH IRINOTECAN FOR THE TREATMENT OF EGFR-EXPRESSINGMETASTATIC COLORECTAL CARCINOMA IN PATIENTS WHO ARE REFRACTORY TOIRINOTECAN-BASED CHEMOTHERAPY",Converted,7/6/2012,
BLA 125084,ERBITUX,CETUXIMAB,ELI LILLY AND COMPANY,8/14/2003,2/12/2004,6.0,"AS A SINGLE AGENT FOR THE TREATMENT OF EGFR-EXPRESSING, METASTATICCOLORECTAL CARCINOMA IN PATIENTS WHO ARE INTOLERANT TO IRINOTECAN-BASED CHEMOTHERAPY",Converted,10/2/2017,
"NDA 021335Supplement 3",GLEEVEC,IMATINIB MESYLATE,NOVARTIS PHARMACEUTICALS,6/28/2002,5/20/2003,10.7,"FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH PH+ CHRONIC PHASE CMLWHOSE DISEASE HAS RECURRED AFTER STEM CELL TRANSPLANT OR WHO ARERESISTANT TO INTERFERON ALPHA THERAPY",Converted,9/27/2006,
NDA 021602,VELCADE,BORTEZOMIB,MILLENNIUM PHARMACEUTICALS,1/21/2003,5/13/2003,3.7,"FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVEDAT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASEPROGRESSION ON THE LAST THERAPY",Converted,3/25/2005,
NDA 021399,IRESSA,GEFITINIB,ASTRAZENECA UK LTD,8/5/2002,5/5/2003,9.0,"AS A MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OFBOTH PLATINUM-BASED AND DOCETAXEL CHEMOTHERAPY","Not Converted - ApplicationWithdrawn",4/25/2012,
BLA 103979,FABRAZYME,AGALSIDASE BETA,GENZYME,6/23/2000,4/24/2003,34.0,FOR THE TREATMENT OF FABRY DISEASE,Converted,3/11/2021,
NDA 021481,FUZEON,ENFUVIRTIDE,HOFFMAN LA ROCHE,9/16/2002,3/13/2003,5.9,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENTOF HIV-1 INFECTION IN TREATMENT EXPERIENCED PATIENTS WITH EVIDENCE OFHIV-1 REPLICATION DESPITE ONGOING ANTIRETROVIRAL THERAPY",Converted,10/15/2004,
,,5/27/2009,,,,,,,,PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)Supplement 4 GLEEVEC IMATINIB MESYLATE NOVARTIS PHARMACEUTICALS 6/28/2002 12/20/2002 5.8 Converted
,,,,,,,,,,NDA 020541 FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE
,,9/16/2005,,,,,,,,Supplement 10 ARIMIDEX ANASTROZOLE ANI PHARMACEUTICALS 3/5/2002 9/5/2002 6.0 RECEPTOR POSITIVE EARLY BREAST CANCER Converted
,,,,,,,,,,IN COMBINATION WITH INFUSIONAL 5-FU/LV FOR THE TREATMENT FOR PATIENTS
,,,,,,,,,,WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM WHOSE DISEASE
,,,,,,,,,,HAS PROGRESSED DURING OR WITHIN 6 MONTHS OF COMPLETION OF FIRST
,,,,,,,,,,LINE THERAPY WITH THE COMBINATION OF BOLUS 5 -FU/LV AND IRINOTECAN
,,1/9/2004,,,,,,,,NDA 021492 ELOXATIN OXALIPLATIN SANOFI AVENTIS 6/24/2002 8/9/2002 1.5 Converted
,,3/20/2006,,,,,,,,NDA 021272 REMODULIN TREPROSTINIL SODIUM UNITED THERAPEUTICS 10/16/2000 5/21/2002 19.1 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION Converted
,,,,,,,,,,FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY LOW-
,,,,,,,,,,"GRADE, FOLLICULAR, OR TRANSFORMED B-CELL NON-HODGKIN'S"
,,,,,,,,,,LYMPHOMA(NHL) OTHER THAN THOSE PATIENTS  WITH RITUXIMAB REFRACTORY
,,9/3/2009,,,,,,,,BLA 125019 ZEVALIN IBRITUMOMAB TIUXETAN SPECTRUM PHARMACEUTICALS 11/1/2000 2/19/2002 15.6 FOLLICULAR NHL Converted
,,,,,,,,,,FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE
,,,,,,,,,,AND/OR METASTATIC MALIGNANT GASTROINTESTINAL
,,,,,,,,,,NDA 021335 STROMAL TUMORS (GIST)
,,9/26/2008,,,,,,,,Supplement 1 GLEEVEC IMATINIB MESYLATE NOVARTIS PHARMACEUTICALS 10/16/2001 2/1/2002 3.6 Converted
,,,,,,,,,,TENOFOVIR DISOPROXIL
,,3/8/2006,,,,,,,,NDA 021356 VIREAD FUMARATE GILEAD SCIENCES 5/1/2001 10/26/2001 5.9 FOR THE TREATMENT OF HIV-1 INFECTION IN ADULTS Converted
,,,,,,,,,,FOR THE TREATMENT OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA(CML) IN
,,,,,,,,,,"BLAST CRISIS, ACCELERATED PHASE, OR IN CHRONIC PHASE AFTER FAILURE OF"
,,12/8/2003,,,,,,,,NDA 021335 GLEEVEC IMATINIB MESYLATE NOVARTIS PHARMACEUTICALS 2/27/2001 5/10/2001 2.4 INTERFERON-ALPHA THERAPY Converted
,,,,,,,,,,FOR THE TREATMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL) IN
,,,,,,,,,,PATIENTS WHO HAVE BEEN TREATED WITH ALKYLATING AGENTS AND WHO HAVE
,,9/19/2007,,,,,,,,BLA 103948 CAMPATH ALEMTUZUMAB GEMZYME 12/23/1999 5/7/2001 16.5 FAILED FLUDARABINE THERAPY Converted
,,,,,,,,,,ABACAVIR SULFATE;
,,,,,,,,,,LAMIVUDINE; ALONE OR IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE
,,5/13/2005,,,,,,,,NDA 021205 TRIZIVIR ZIDOVUDINE VIIV HEALTHCARE 12/17/1999 11/14/2000 10.9 TREATMENT OF HIV-1 INFECTION Converted
,,,,,,,,,,IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT
,,,,,,,,,,KALETRA OF HIV-1 INFECTION IN ADULTS AND  PEDIATRIC PATIENTS AGE SIX MONTHS OR
,,11/27/2002,,,,,,,,NDA 021226 (capsules) LOPINAVIR: RITONAVIR ABBVIE 6/1/2000 9/15/2000 3.5 OLDER Converted
,,,,,,,,,,IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT
,,,,,,,,,,KALETRA OF HIV-1 INFECTION IN ADULTS AND  PEDIATRIC PATIENTS AGE SIX MONTHS OR
,,11/27/2002,,,,,,,,NDA 021251 (oral solution) LOPINAVIR: RITONAVIR ABBVIE 6/1/2000 9/15/2000 3.5 OLDER Converted
,,,,,,,,,,NDA 019858 Not Converted - Application
,,6/4/2004,,,,,,,,Supplement 21 CIPRO CIPROFLOXACIN BAYER HEALTHCARE PHARMACEUTICALS 3/2/2000 8/30/2000 6.0 FOR THE TREATMENT OF INHALATIONAL ANTHRAX (POST-EXPOSURE) Withdrawn
,,,,,,,,,,NDA 020780 Not Converted - Application
,,6/4/2004,,,,,,,,Supplement 8 CIPRO CIPROFLOXACIN BAYER HEALTHCARE PHARMACEUTICALS 3/2/2000 8/30/2000 6.0 FOR THE TREATMENT OF INHALATIONAL ANTHRAX (POST-EXPOSURE) Withdrawn
,,,,,,,,,,NDA 019537
,,1/7/2005,,,,,,,,Supplement 38 CIPRO CIPROFLOXACIN BAYER HEALTHCARE PHARMACEUTICALS 3/1/2000 8/30/2000 6.0 FOR THE TREATMENT OF INHALATIONAL ANTHRAX (POST-EXPOSURE) Converted
,,,,,,,,,,NDA 019847
,,1/7/2005,,,,,,,,Supplement 24 CIPRO CIPROFLOXACIN BAYER HEALTHCARE PHARMACEUTICALS 3/2/2000 8/30/2000 6.0 FOR THE TREATMENT OF INHALATIONAL ANTHRAX (POST-EXPOSURE) Converted
,,,,,,,,,,NDA 019857
,,1/7/2005,,,,,,,,Supplement 27 CIPRO CIPROFLOXACIN BAYER HEALTHCARE PHARMACEUTICALS 3/2/2000 8/30/2000 6.0 FOR THE TREATMENT OF INHALATIONAL ANTHRAX (POST-EXPOSURE) Converted
,,,,,,,,,,FOR THE TREATMENT OF PATIENTS WITH CD33 POSITIVE ACUTE MYELOID
,,11/28/2011,,,,,,,,Not Converted - Application ARE NOT CONSIDERED CANDIDATES FOR CYTOTOXIC CHEMOTHERAPYNDA 021174 MYLOTARG LEUKEMIA IN FIRST RELAPSE WHO ARE 60 YEARS OF AGE OR OLDER AND WHO GEMTUZUMAB OZOGAMICIN WYETH PHARMACEUTICALS 10/29/1999 5/17/2000 6.6 Withdrawn
,,,,,,,,,,TO REDUCE THE NUMBER OF  ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL
,,,,,,,,,,"NDA 021156 ADENOMATOUS POLYPOSIS PATIENTS, AS AN ADJUNCT TO USUSAL CARE Not Converted - Indication"
,,6/8/2012,,,,,,,,Original 1 CELEBREX CELECOXIB GD SEARLE 6/25/1999 12/23/1999 6.0 Withdrawn
,,,,,,,,,,DALFOPRISTIN/QUINUPRI FOR THE TREATMENT OF VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM Not Converted - Application
,,11/12/2010 2,,,,,,,,NDA 050747 SYNERCID STIN KING PHARMACEUTICALS 9/5/1997 9/21/1999 7.8† (VREF) Withdrawn
,,,,,,,,,,FOR THE TREATMENT OF ADULT PATIENTS WITH REFRACTORY ANAPLASTIC
,,3/15/2005,,,,,,,,NDA 021029 TEMODAR TEMOZOLOMIDE MERCK SHARP & DOHME 8/13/1998 8/11/1999 11.9 ASTROCYTOMA Converted
,,,,,,,,,,FOR THE TREATMENT OF METASTATIC CARCINOMA OF THE OVARY IN PATIENTS
,,,,,,,,,,NDA 050718 DOXORUBICIN WITH DISEASE THAT IS REFRACTORY TO BOTH PACILTAXEL-AND PLATINUM-
,,1/28/2005,,,,,,,,Supplement 6 DOXIL HYDROCHLORIDE JANSSEN PRODUCTS LP 12/29/1998 6/28/1999 6.0 BASED CHEMOTHERAPY REGIMENS Converted
,,,,,,,,,,"AGENERASE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, FOR THE TREATMENT"
,,5/11/2001,,,,,,,,NDA 021007 (capsules) AMPRENAVIR GLAXOSMITHKLINE 10/16/1998 4/15/1999 6.0 OF HIV-1 INFECTION Converted
,,,,,,,,,,"AGENERASE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, FOR THE TREATMENT"
,,5/11/2001,,,,,,,,NDA 021039 (oral solution) AMPRENAVIR GLAXOSMITHKLINE 12/8/1998 4/15/1999 4.2 OF HIV-1 INFECTION Converted
,,4/19/2007,,,,,,,,NDA 021041 DEPOCYT CYTARABINE(liposomal) PACIRA PHARMACEUTICALS 10/5/1998 4/1/1999 5.9 FOR THE INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS Converted
,,,,,,,,,,FOR THE TREATMENT OF PERSISTENT OR RECURRENT CUTANEOUS T-CELL
,,,,,,,,,,LYMPHOMA WHOSE MALIGNANT CELLS EXPRESS THE CD25 COMPONENT OF THE
,,10/15/2008,,,,,,,,BLA 103767 ONTAK DENILEUKIN DIFTITOX EISAI 12/9/1997 2/5/1999 13.9 IL-2 RECEPTOR Converted
"As of March 31, 2024",,,,,,,,,,
Total Approvals 310,,,,,,,,,,
NDA 020977,"ZIAGEN(tablets)",ABACAVIR SULFATE,VIIV HEALTHCARE,6/24/1998,12/17/1998,5.8,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, FOR THE TREATMENTOF HIV-1 INFECTION",Converted,4/15/2004,
NDA 020978,"ZIAGEN(oral solution)",ABACAVIR SULFATE,VIIV HEALTHCARE,6/24/1998,12/17/1998,5.8,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, FOR THE TREATMENTOF HIV-1 INFECTION",Converted,4/15/2004,
NDA 020972,SUSTIVA,EFAVIRENZ,BRISTOL MYERS SQUIBB,6/11/1998,9/17/1998,3.2,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, FOR THE TREATMENTOF HIV-1 INFECTION",Converted,2/9/2000,
"NDA 020636Supplement 9",VIRAMUNE,NEVIRAPINE,"BOEHRINGER INGELHEIMPHARMACEUTICALS",3/16/1998,9/11/1998,5.9,"PROVIDES FOR AN ORAL SUSPENSION IN COMBINATION WITH OTHERANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION",Converted,3/27/2002,
NDA 020933,VIRAMUNE,NEVIRAPINE,"BOEHRINGER INGELHEIMPHARMACEUTICALS",4/20/1998,9/11/1998,4.7,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR TREATMENT OFHIV-1 INFECTION",Converted,3/27/2002,
BLA 103772,REMICADE,INFLIXIMAB,JANSSEN BIOTECH,12/30/1997,8/24/1998,7.8,"FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASEFOR THE REDUCTION OF THE SIGNS AND SYMPTOMS, IN PATIENTS WHO HAVE ANINADEQUATE RESPONSE TO CONVENTIONAL THERAPIES AND TREATMENT OFPATIENTS WITH FISTULIZING CROHN'S DISEASE FOR THE REDUCTION IN THENUMBER OF DRAINING ENTEROCUTANEOUS FISTULAS",Converted,4/1/2003,
NDA 021024,PRIFTIN,RIFAPENTINE,SANOFI AVENTIS,12/22/1997,6/22/1998,6.0,FOR THE TREATMENT OF PULMONARY TUBERCULOSIS,Converted,6/1/2009,
NDA 019832,SULFAMYLON,MAFENIDE ACETATE,MYLAN INSTITUTIONAL,3/31/1997,6/5/1998,14.2†,"FOR USE AS ADJUNCTIVE TOPICAL ANTIMICROBIAL AGENT TO CONTROLBACTERIAL INFECTION WHEN USED UNDER MOIST DRESSINGS OVER MESHEDAUTOGRAPFTS ON EXCISED BURN WOUNDS","Not Converted - ApplicationWithdrawn",11/30/2022,
NDA 020896,XELODA,CAPECITABINE,HOFFMAN LA ROCHE,10/31/1997,4/30/1998,6.0,"FOR THE TREATMENT OF METASTATIC BREAST CANCER RESISTANT TO BOTHPACILTAXEL AND AN ANTHRACYCLINE-CONTAINING CHEMOTHERAPY REGIMENOR RESISTANT TO PACILTAXEL AND FOR WHOM FURTHER ANTHRACYCLINETHERAPY AY BE CONTRAINDICATED",Converted,9/7/2001,
NDA 020705,RESCRIPTOR,DELAVIRDINE MESYLATE,VIIV HEALTHCARE,7/15/1996,4/4/1997,8.6,"FOR THE TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH APPROPRIATEANTIRETROVIRAL AGENTS WHEN THERPAY IS WARRANTED",Converted,5/16/2001,
NDA 020778,"VIRACEPT(oral powder)",NELFINAVIR MESYLATE,AGOURON PHARMACEUTICALS,12/26/1996,3/14/1997,2.6,FOR THE TREATMENT OF HIV INFECTION WHEN THERAPY IS WARRANTED,Converted,5/17/2000,
NDA 020779,VIRACEPT (tablets),NELFINAVIR MESYLATE,AGOURON PHARMACEUTICALS,12/26/1996,3/14/1997,2.6,"FOR THE TREATMENT OF HIV INFECTION WHEN ANTIRETROVIRAL THERAPY ISWARRANTED",Converted,5/17/2000,
NDA 019815,PROAMATINE,"MIDODRINEHYDROCHLORIDE",SHIRE DEVELOPMENT,9/25/1995,9/6/1996,11.4†,FOR THE TREATMENT OF SYMPTOMATIC ORTHOSTATIC HYPROTENSION (OH),Not Yet Converted,,
NDA 020604,SEROSTIM,SOMATROPIN,EMD SERONO,9/11/1995,8/23/1996,11.4,FOR THE TREATMENT OF AIDS WASTING AND CACHEXIA,Converted,8/29/2003,
NDA 020636,VIRAMUNE,NEVIRAPINE,"BOEHRINGER INGELHEIMPHARMACEUTICALS",2/23/1996,6/21/1996,3.9,"IN COMBINATION WITH NUCLEOSIDE ANALOGUES  FOR THE TREATMENT OF  HIV-1 INFECTED ADULTS WHO HAVE EXPREIENCED CLINICAL AND/ORIMMUNOLOGICAL DETERIORATION",Converted,3/27/2002,
NDA 020571,CAMPTOSAR,"IRINOTECAN HCLTRIHYDROTE",PFIZER,12/28/1995,6/14/1996,5.6,"FOR THE TREATMENT OF METASTATIC CARCINOMA OF THE COLON OR RECTUMWHOSES DIEASE HAS PROGRESSED FOLLOWING 5-FU-BASED THERAPYC",Converted,10/22/1998,
NDA 020449,TAXOTERE,DOCETAXEL,SANOFI AVENTIS,7/27/1994,5/14/1996,21.6,"FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATICBREAST CARCINOMA WHO HAVE PROGRESSED DURING ANTHRACYCLINE-BASEDTHERAPY OR HAVE RELAPSED DURING ANTHRACYCLINE-BASED ADJUVANTTHERAPY",Converted,6/22/1998,
"NDA 020221Supplement 2",ETHYOL,AMIFOSTINE,CLINIGEN HEALTHCARE,2/9/1996,3/15/1996,1.2,"TO REDUCT CUMULATIVE RENAL TOXICITY ASSOCIATED WITH REPEATEDADMINSTATIONS OF CISPLATIN IN PATIENTS WITH  NON-SMALL CELL LUNGCANCER","Not Converted - IndicationWithdrawn",3/28/2006 3,
NDA 020685,CRIXIVAN,INDINAVIR SULFATE,MERCK SHARP & DOHME,1/31/1996,3/13/1996,1.4,"FOR THE TREATMENT OF HIV-1 INFECTION IN ADULTS WHEN THERAPY ISWARRANTED",Converted,2/6/1998,
NDA 020659,"NORVIR(oral solution)",RITONAVIR,ABBOTT LABORATORIES,12/21/1995,3/1/1996,2.3,"IN COMBINATION WITH NUCLEOSIDE ANALOGS OR AS MONOTHERPY FOR THETREATMENT OF HIV INFECTION WHEN THERAPY IS WARRANTED",Converted,5/26/1999,
NDA 020680,"NORVIR(oral solution)",RITONAVIR,ABBOTT LABORATORIES,12/21/1995,3/1/1996,2.3,"IN COMBINATION WITH NUCLEOSIDE ANALOGS OR AS MONOTHERPY FOR THETREATMENT OF HIV INFECTION WHEN THERAPY IS WARRANTED",Converted,5/26/1999,
NDA 020628,INVIRASE,SAQUINAVIR MESYLATE,HOFFMAN LA ROCHE,8/31/1995,12/6/1995,3.2,"IN COMBINATION WITH NUCLEOSIDE ANALOGS FOR THE TREATMENT OFADVANCED HIV INFECTION IN SELECTED PATIENTS",Converted,9/27/1996,
NDA 050718,DOXIL,"DOXORUBICINHYDROCHLORIDE",JANSSEN PRODUCTS LP,9/7/1994,11/17/1995,14.3,"FOR THE TREATMENT OF KAPOSI'S SARCOMA IN AIDS PATIENTS WITH DISEASETHAT HAS PROGRESSED ON PRIOR COMBINATION CHEMOTHERAPY OR INPATIENTS WHO ARE INTOLERANT TO SUCH THERAPY",Converted,6/10/2008,
NDA 020564,EPIVIR,LAMIVUDINE,VIIV HEALTHCARE,7/7/1995,11/17/1995,4.4,"IN COMBINATION WITH RETROVIR (ZIDOVUDINE) FOR THE TREATMENT OF HIVINFECTION WHEN THERAPY IS WARRANTED BASED ON CLINICAL AND/ORIMMUNOLOGICAL EVIDENCE OF DISEASE PROGRESSION",Converted,4/11/1997,
"As of March 31, 2024",,,,,,,,,,
Total Approvals 310,,,,,,,,,,
NDA 020596,EPIVIR,LAMIVUDINE,VIIV HEALTHCARE,7/7/1995,11/17/1995,4.4,"IN COMBINATION WITH RETROVIR (ZIDOVUDINE) FOR THE TREATMENT OF HIVINFECTION WHEN THERAPY IS WARRANTED BASED ON CLINICAL AND/ORIMMUNOLOGICAL EVIDENCE OF DISEASE PROGRESSION",Converted,4/11/1997,
NDA 020498,CASODEX,BICALUTAMIDE,ANI PHARMACEUTICALS,9/14/1994,10/4/1995,12.7,"IN COMBINATION THERAPY WITH AN LHRH ANALOGUE  FOR THE TREATMENT OFADVANCED PROSTATE CANCER",Converted,12/12/1997,
NDA 020212,ZINECARD,"DEXRAZOXANEHYDROCHLORIDE",PHARMACIA AND UPJOHN,8/5/1994,5/26/1995,9.7†,"FOR THE PREVENTION OF CARDIOMYOPATHY ASSOCIATED WITH DOXORUBICINADMINISTRATION",Converted,10/31/2002,
NDA 020412,ZERIT,STAVUDINE,BRISTOL MYERS SQUIBB,12/28/1993,6/24/1994,5.9,"FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED HIV INFECTION WHOARE INTOLERANT OF APPROVED THERAPIES WITH PROVEN CLINICAL BENEFIT ORWHO HAVE EXPERIENCED SIGNIFICANT CLINICAL OR IMMUNOLOGICALDETERIORATION WHILE RECEIVING THESE THERAPIES OR FOR WHOM SUCHTHERAPIES ARE CONTRAINDICATED",Converted,12/21/1995,
"NDA 050697Original 1",BIAXIN,CLARITHROMYCIN,ABBVIE,11/2/1992,12/23/1993,13.7,"FOR THE TREATMENT OF DISSEMINATED MYCOBACTERIAL INFECTIONS DUE TOMYCOBACTERIUM AVIUM AND MYCOBACTERIUM INTRACELLULARE",Converted,5/24/2002,
NDA 050698,BIAXIN,CLARITHROMYCIN,ABBVIE,11/2/1992,12/23/1993,13.7,"FOR THE TREATMENT OF DISSEMINATED MYCOBACTERIAL INFECTIONS DUE TOMYCOBACTERIUM AVIUM AND MYCOBACTERIUM INTRACELLULARE",Converted,5/24/2002,
BLA 103471,BETASERON,INTERFERON BETA-1B,BAYER HEALTHCARE PHARMACEUTICALS,6/18/1992,7/23/1993,13.2,"USE IN AMBULATORY PATIENTS WITH RELAPSING-REMITTING MULTIPLESCLEROSIS TO REDUCE THE FREQUENCY OF CLINICAL EXACERBATIONS",Converted,3/14/2003,
NDA 020199,HIVID,ZALCITABINE,HOFFMAN LA ROCHE,10/31/1991,6/19/1992,7.6,"IN COMBINATION WITH ZIDOVUDINE FOR THE TREATMENT OF ADULT PATIENTSWITH ADVANCED HIV INFECTION (CD4 CELL COUNTS < 300 CELLS/MM3) WHOHAVE DEMONSTRATED SIGNIFICANT CLINICAL OR IMMUNOLOGICDETERIORATION",Converted,6/26/1996,
"†-- Total approval time was adjusted based on management decision.  This is a legacy practice and is no longer exercised.1. Proprietary name yet to be determined2. Federal Register Date, which may be different than applicant submission or FDA action date",,,,,,,,,,
3. Date of the labeling supplement approval that removed this indication,,,,,,,,,,
4. This accelerated approval is for a new dosing regimen that is applicable across multiple indications. See FDA Press Release of 8-APR-20 for more details,,,,,,,,,,
5. Indication withdrawn on 10-JUN-22,,,,,,,,,,
The Therapeutic Biologic Products transferred from CBER to CDER effective 1-Oct-03,,,,,,,,,,
,,,,,,,,,,
